REVIEW

Molecular regulation of follicle-stimulating hormone synthesis, secretion and action

Nandana Das¹ and T Rajendra Kumar^{1,2,3}¹Division of Reproductive Sciences, University of Colorado Anschutz Medical Campus, Aurora, Colorado, USA²Division of Reproductive Endocrinology and Infertility, University of Colorado Anschutz Medical Campus, Aurora, Colorado, USA³Department of Obstetrics and Gynecology, University of Colorado Anschutz Medical Campus, Aurora, Colorado, USACorrespondence should be addressed to T R Kumar: raj.kumar@ucdenver.edu

Abstract

Follicle-stimulating hormone (FSH) plays fundamental roles in male and female fertility. FSH is a heterodimeric glycoprotein expressed by gonadotrophs in the anterior pituitary. The hormone-specific FSH β -subunit is non-covalently associated with the common α -subunit that is also present in the luteinizing hormone (LH), another gonadotrophic hormone secreted by gonadotrophs and thyroid-stimulating hormone (TSH) secreted by thyrotrophs. Several decades of research led to the purification, structural characterization and physiological regulation of FSH in a variety of species including humans. With the advent of molecular tools, availability of immortalized gonadotroph cell lines and genetically modified mouse models, our knowledge on molecular mechanisms of FSH regulation has tremendously expanded. Several key players that regulate FSH synthesis, sorting, secretion and action in gonads and extragonadal tissues have been identified in a physiological setting. Novel post-transcriptional and post-translational regulatory mechanisms have also been identified that provide additional layers of regulation mediating FSH homeostasis. Recombinant human FSH analogs hold promise for a variety of clinical applications, whereas blocking antibodies against FSH may prove efficacious for preventing age-dependent bone loss and adiposity. It is anticipated that several exciting new discoveries uncovering all aspects of FSH biology will soon be forthcoming.

Key Words

- ▶ pituitary
- ▶ FSH
- ▶ LH
- ▶ testis
- ▶ ovary
- ▶ extragonadal
- ▶ reproduction
- ▶ miRNA
- ▶ transgenic mice

*Journal of Molecular
Endocrinology*
(2018) **60**, R131–R155

Introduction

Follicle-stimulating hormone (FSH) is a critical regulator of reproductive physiology. It is a heterodimeric glycoprotein that consists of two distinct subunits, α and β . The α -subunit is common to all pituitary and placental glycoprotein hormones, whereas the β -subunit is hormone-specific and the heterodimer confers biological activity. The overall regulation of FSH involves control at the level of subunit gene transcription, translation, dimer assembly, formation of different isoforms that influence synthesis and release and physiological functions

(Pierce & Parsons 1981, Bousfield *et al.* 2006, Ulloa-Aguirre *et al.* 2017, Narayan *et al.* 2018). While earlier research has established FSH as an indispensable player in proper functioning of the reproductive axis, recent findings indicate its much widespread actions. In this review, we provide the molecular mechanisms driving each phase of FSH regulation from the initiation of its synthesis to ultimate physiological effects, with a focus on identifying the interlink between the encompassing effector pathways.

Transcriptional regulation of α -glycoprotein hormone subunit -encoding gene

The α -subunit is expressed in trophoblast, gonadotroph and thyrotroph cell types, and its expression is differentially regulated depending on the specific pituitary or placental cell type.

An earlier study showed that a short 18-bp sequence serves as a cAMP response element that is independent of other regulatory elements around the 5' flanking region of the human *CGA* promoter (Silver *et al.* 1987). In fact, proteins that bind to this cAMP response element positively regulate the alpha-subunit gene by cooperative interaction (Nilson *et al.* 1989). Another study suggested that placenta-specific expression of human *CGA* may be evolutionary outcome of a functional cAMP response element, whereas a different cis-acting element might be responsible for its expression in the pituitary (Bokar *et al.* 1989). It is also known that gonadotropin-releasing hormone (GnRH), produced by the hypothalamus, is a key regulator of *Cga* mRNA expression (Burrin & Jameson 1989). Transcription of *Cga* in cultured rat pituitary cells was found to be altered upon pulsatile GnRH administration (Shupnik 1990). Later, two DNA elements were identified that were involved in GnRH-mediated expression of the mouse *Cga* (Schoderbek *et al.* 1993). Moreover, the co-localization of GnRH and phorbol myristate acetate (an activator of protein kinase C) responsiveness indicates that the effect of GnRH on transcriptional regulation of mouse *Cga* is most likely through the PKC pathway.

Various groups also investigated signaling pathways in addition to deciphering DNA elements and transcription factors to better understand their regulatory mechanisms. Maurer and coworkers identified two unrelated DNA elements and designated them as GnRH response element (GnRH-RE), an element that was adequate to allow GnRH response, and a pituitary glycoprotein hormone basal element (PGBE), that enhanced basal expression of the α -subunit (Maurer *et al.* 1999). GnRH-RE was found to encompass a consensus binding region for the E26 transformation-specific (Ets) family of transcription factors and demonstrated that GnRH-induced activation of MAPK pathway, mediated by GnRH-RE, is required and also sufficient enough for the transcriptional activation of *Cga* gene. Recently, it was established that GnRH-mediated activation of *Cga* expression requires stress-activated protein kinase 1 (MSK1) and mitogen through an epigenetically regulated mechanism involving histone modifications (Haj *et al.* 2017).

Other than GnRH-associated response elements, two upstream regions of the *Cga* gene were identified that distinctly regulate its basal promoter transcription and PMA-stimulated promoter activity independently in mature gonadotroph cells. Steroidogenic factor 1 (SF-1) is involved in mediating these activities through its binding site in the promoter (Fowkes *et al.* 2002). Fowkes and coworkers have also shown that GATA factors may be related to ERK activation of transcription, and PKC-induced transcription relies partially on ERK interaction on elements downstream of -244 bp of the promoter. Another study from this group reported that SF-1 also significantly increases forskolin-stimulated *Cga* transcription and a phosphorylation site at the Serine 203 residue seems to be necessary for the activity (Fowkes & Burrin 2003). A recent study has identified the Msh homeobox 1 (Msx1) as a negative regulator that represses the gonadotroph-specific *Cga* expression. A decline in Msx1 expression in a temporal manner relieves this repression allowing production of the gonadotropic hormones (Xie *et al.* 2013). Another study validated the role of Msx1 as a transcription repressor of the *Cga* gene and demonstrated that the mechanism by which Msx1 regulates inhibition of *Cga* gene expression involves its interaction with the TATA-binding protein in thyrotrophs (Park *et al.* 2015). Other important factors of *Cga* gene regulation includes Sine oculis-related homeobox 3 (SIX3) homeodomain transcription factors that represses transcription of the alpha-subunit in immature gonadotroph cell lines (Xie *et al.* 2015).

Transcriptional regulation of FSH β subunit-encoding gene

The β -subunit of FSH confers the specific biological activity of FSH dimer. Hence, synthesis of the FSH β subunit is a rate-limiting step for the production of the biologically active FSH (Papavasiliou *et al.* 1986). The production of FSH β subunit is under tight regulation, and one of the most important points of control is at the level of FSH β -encoding gene transcription. Its expression is also under a critical temporal regulation as FSH β -encoding mRNA level was observed to increase about 4- to 5-fold during afternoon of proestrous while the increase was about 3-fold during estrus in rodents (Ortolano *et al.* 1988, Halvorson *et al.* 1994). Among many regulatory factors, GnRH and activins are key players in controlling FSH β expression and both these act through independent as well as related pathways.

Regulation of FSH β -encoding gene expression by GnRH

GnRH is released in a pulsatile manner from neurons in the hypothalamus and reaches pituitary via the hypophyseal-portal system. GnRH receptor is specifically expressed by the gonadotroph cells (Tsutsumi *et al.* 1992, Stojilkovic *et al.* 1994, Kaiser *et al.* 1997). GnRH pulse frequency determines the rate of FSH β production as many studies have shown that a decrease in GnRH pulse frequency favors FSH β production over that of LH β (Haisenleder *et al.* 1988, Dalkin *et al.* 1989, 2001). FSH levels in serum are reduced by 60–90% in mice without GnRH (Mason *et al.* 1986) and administration of GnRH to rats increased *Fshb* mRNA expression by fourfold (Dalkin *et al.* 2001), indicating that GnRH regulation of FSH β takes place at the level of transcription.

Of the several proposed effector pathways by which GnRH regulates mouse FSH β expression, the major ones include PKC and MAPK signaling pathways (Bonfil *et al.* 2004, Coss *et al.* 2004, Liu *et al.* 2005). The GnRH ligand binding activates GnRH receptors (GnRHR), which increase the activities of calcium/calmodulin kinase II and protein kinase C (PKC) (Liu *et al.* 2002, Haisenleder *et al.* 2003) via activation of Gq and G11 family of G-proteins (Stanislaus *et al.* 1997). GnRHR activation also initiates induction of distinct mitogen-activated protein kinase (MAPK) pathways, namely ERK1/2, p38 and JNK (Roberson *et al.* 1995, Sundaresan *et al.* 1996, Liu *et al.* 2002). Activation of the MAPK pathway is achieved via PKC (Naor 2009) or through GnRHR association with Raf and calmodulin, which play a key role in mediating Ca²⁺ action on ERK activation, independent of the phospholipase C activity (Roberson *et al.* 2005).

GnRH also regulates FSH β expression via induction of immediate early genes (IEGs), which includes Jun, Fos, Atf3 and Egr1. One such IEG product is activator protein-1 (AP-1), which consists of various Fos and Jun dimeric isoforms (c-Fos, Fra-1, Fra-2, FosB, c-Jun, JunB and JunD) that are induced by GnRH (Wurmbach *et al.* 2001, Kakar *et al.* 2003). Regulation of Jun and Atf3 by GnRH requires calcium, calcineurin and nuclear factor of activated T cells (NFAT) that confers responsiveness to various genes responsible for FSH synthesis (Binder *et al.* 2012). Strahl and coworkers identified two AP-1-binding sites within the ovine *Fshb* promoter sequence that are sufficient enough to stimulate its expression independently (Strahl *et al.* 1997, 1998). MAPK-mediated GnRH induction of murine *Fshb* takes place via AP-1-interactive sites, where c-Jun and FosB bind to induce the promoter (Liu *et al.*

2002, Coss *et al.* 2004). AP-1 proteins have also been shown to regulate human *Fshb* promoter activity via two specific response elements (Wang *et al.* 2008). Integrated GnRH response also requires factors that are associated with basal *Fshb* expression, like nuclear transcription factor Y (NF-Y) in mouse and upstream stimulatory factor 1 (USF1) in rat, and the mechanism involves interactions of these factors with AP-1 (Coss *et al.* 2004, Ciccone *et al.* 2008). *c-Fos*-knockout mice demonstrate small ovaries and atretic follicles (Johnson *et al.* 1992), similar to phenotypes of *Fshb*-knockout mice (Kumar *et al.* 1997) indicating a possible key role of this proto-oncogene in regulation of FSH β . GnRH is also reported to increase c-Fos half-life, thus in turn resulting in increased FSH β expression (Reddy *et al.* 2013). In addition to these factors, the CREB transcription factor was found to be involved in GnRH-regulated *Fshb* expression in rats through interaction at a homologous CRE/AP-1 site (Ciccone *et al.* 2008), although mice deficient in CREB exhibit unaltered FSH levels suggesting a species-specific role of this factor. It is further demonstrated that inducible cAMP early repressors (ICER) antagonize the CREB stimulatory action to attenuate *Fshb* transcription at high GnRH pulse frequencies (Ciccone *et al.* 2010). It has been recently reported that ICER influenced GnRH control of *Fshb* expression is mediated via ERK1/2 regulatory pathway (Thompson *et al.* 2016).

GnRH stimulation was recently shown to increase intracellular reactive oxygen species (ROS) via NOX/DUOX-mediated activity, suggesting a new concept of ROS involvement as a signaling intermediate in response to GnRH induction (Kim & Lawson 2015). This finding further opens up the possibility that ROS generated by other processes may also influence GnRH stimulation of FSH expression. GnRH induces β -catenin, a classical intermediate of the WNT signaling pathway, which is shown to influence FSH β production in a murine model (Boerboom *et al.* 2015). Another proposed factor is phosphoprotein-enriched in astrocytes 15 (PEA-15) an ERK scaffolding protein present in cytosol. It was suggested to mediate convergence of PKC and MAPK/ERK pathways induced by GnRH (Choi *et al.* 2011). GABA alpha4beta3delta receptor agonist DS1 was recently reported to stimulate FSH β expression in association with the ERK signaling pathway through the activation of *Gnrhr* promoter (Mijiddorj *et al.* 2015). In an alternate mechanism, it was suggested that GnRH regulation of Homer protein homolog 1 (Homer 1) splicing may contribute to FSH expression (Wang *et al.* 2014b).

Regulation of FSH β expression by activin-follistatin-inhibin loop

Activin is a dimeric peptide composed of two identical beta subunits that can have two major isoforms, β A and β B. Activins were identified as gonadal peptides, which stimulate the production of FSH (Ling *et al.* 1986, Vale *et al.* 1986). They bind to the type II receptor, resulting in phosphorylation of the type I receptor (Attisano & Wrana 2002), which then consequently phosphorylates the intracellular proteins Smad2 and Smad3 initiating the signal response cascade. The phosphorylated proteins bind to Smad4 and forms the 'activating complex', which is then translocated to the nucleus where it binds DNA through a direct interaction of Smad-binding elements (SBE) with specific domains on Smad3 and Smad4 (Massague 1998, Shi *et al.* 1998) to induce transcription of the FSH β -encoding gene (Bernard & Tran 2013). It was previously reported that activin induces increased FSH release from the pituitary (Ling *et al.* 1986) and FSH β expression in gonadotropes (Weiss *et al.* 1995). Three prominent activin-response elements have been identified in the FSH β -encoding gene promoter region till date. A classical Smad-binding consensus sequence at -267, consisting a palindrome GTCTAGAC, was first proposed to be an important response element in rodents (Bernard 2004, Gregory *et al.* 2005, Suszko *et al.* 2005), but was later on found to have no significant contribution in activin induction of *Fshb* (Coss *et al.* 2007, McGillivray *et al.* 2007). This specific site is not present in human *FSHB* promoter. Bailey and coworkers identified three separate elements associated with FSH β -encoding gene promoter, which were essential for activin induction, and these proximal sites are found to be present in all species examined (Bailey *et al.* 2004). SMAD-associated factors, like Pre-B-cell leukemia transcription factor 1 (Pbx1) and PBX/knotted 1 homeobox 1 (Prep1) proteins were also identified that seem to bind the response elements and aid in tethering of Smads to the promoter following activation (Suszko *et al.* 2003, Bailey *et al.* 2004). In an alternate mechanism, paired-like homeodomain transcription factors 1 and 2 (PITX1 and 2) regulate SMAD 2/3/4-stimulated *Fshb* transcription through a conserved cis-element (Lamba *et al.* 2008). It was recently established that SMAD4 and forkhead box L2 (FOXL2) are essential factors for *in vivo* transcription of *Fshb* (Fortin *et al.* 2014). Other than the mostly studied SMAD-mediated activation, TAK1 signaling pathway, a member of the MAPKKK family, was recognized as a potent player in the induction of FSH β -encoding gene

transcription by activin (Safwat *et al.* 2005). But, a recent study contradicted the idea by demonstrating that activin A signaling is independent of the TAK1 (MAP3K7)/p38 MAPK pathway and depends on SMAD proteins (Wang & Bernard 2012). Other factors that can stimulate activin induction include morphogenetic proteins (BMPs) (Otsuka & Shimasaki 2002, Lee *et al.* 2007, Nicol *et al.* 2008), but their mechanism of action and associated signaling pathways are not clear.

Inhibin and follistatin are two potent antagonists of activin, regulating its inductive effects via two distinct inhibitory loops. Inhibin is a heterodimer that consists of one subunit identical to activin and another unique alpha-subunit (Nakamura *et al.* 1998). The production of inhibin from ovarian granulosa cells is stimulated by FSH, which in turn downregulates FSH production. The proposed mechanism of inhibin actions includes competitive inhibition at activin receptors or interaction at inhibin-specific-binding sites that alters active activin-binding process (Gregory & Kaiser 2004, Robertson *et al.* 2004). On the other hand, follistatin, a glycoprotein having nearly ubiquitous expression in various tissues, inhibits activin actions by directly binding to it (Shimasaki *et al.* 1988). Taken together, functions of activin, inhibin and follistatin forms a complex regulatory loop that tightly controls FSH production at the level of transcription. A considerable inter-species variation of FSH regulation at the level of transcription was observed as evidenced by the identification of different TATA box and other regulatory elements across species by *in silico* analysis (Kutteyil *et al.* 2017).

Regulation of FSH β -encoding gene expression by steroid hormones

The expression of FSH β -encoding gene is under feedback regulation by estrogen and progesterone, both acting at the level of hypothalamus and anterior pituitary. But in rodents, estrogen does not directly modulate *Fshb* gene expression and seems to have only a partial effect in FSH negative feedback, as post-ovariectomy estrogen treatment does not show total suppression (Shupnik *et al.* 1988). It was also reported that the expression of *Fshb* mRNA was not altered in ovariectomized rats (Shupnik *et al.* 1989, Dalkin *et al.* 1993) or in rat pituitary tissue (Shupnik & Fallest 1994). An *in vitro* study with murine *Fshb* promoter also supported these results showing that *Fshb* expression was not stimulated by estrogen (Thackray *et al.* 2006). Hence, it could be postulated that estrogen indirectly modulates the expression of

the FSH β -encoding gene by regulating the actions of GnRH, activin or other effectors. It was, in fact, reported that estrogen receptor alpha (ER α)-knockout mouse had higher expression of activin B in pituitary (Couse *et al.* 2003).

Progesterone (P4), unlike estrogen, imparts both positive and negative feedback on FSH β -encoding gene expression. It acts indirectly at the level of hypothalamus by regulating GnRH production and directly in the anterior pituitary (Levine *et al.* 2001). Many studies have hypothesized that FSH β -encoding gene expression in the anterior pituitary is induced by progestins (reviewed in detail in Burger *et al.* 2004). *Fshb* mRNA expression and secretion were blocked by P4 antagonists during preovulatory (Ringstrom *et al.* 1997) and secondary FSH surge (Knox & Schwartz 1992) in rats. Murine *Fshb* promoter was also observed to be induced by P4 *in vitro* (Thackray *et al.* 2006). A region of the DNA from –500 to –95 of the proximal promoter, which was previously shown to consist of six response elements in both ovine and mouse genes, was identified to be responsible for progesterone responsiveness, thus explaining the direct involvement of P4 in *Fshb* gene expression.

Androgens can also directly upregulate FSH β -encoding mRNA levels in the pituitary. Various studies have reported that testosterone administration on GnRH antagonist-treated rodents showed increased *Fshb* mRNA production (Paul *et al.* 1990, Wierman & Wang 1990, Burger *et al.* 2004). *In vitro* studies have established that only gonadotrope cells are enough for the induction of FSH β -encoding mRNA expression, suggesting that the androgen effect takes place uniquely at the pituitary, and the androgen-driven activation of ovine and murine *Fshb* promoters involved the direct binding of androgen receptors to specific hormone response elements (Spady *et al.* 2004, Thackray *et al.* 2006). However, unlike the previous reports, testosterone-regulated *Fshb* transcription is mediated through the activin signaling pathway in both rat model and cell line studies (Burger *et al.* 2007).

Other than estrogen, progesterone and androgen, glucocorticoids are also known to regulate FSH β production in the anterior pituitary. *Fshb* expression was shown to selectively increase upon glucocorticoid administration in both rats and primary pituitary cultures (Ringstrom *et al.* 1991, McAndrews *et al.* 1994, Kilen *et al.* 1996, Leal *et al.* 2003). A summary of major players in transcriptional regulation of FSH subunits is shown in Fig. 1.

Other regulators of FSH β -encoding gene expression

Other than previously discussed major regulatory pathways, many novel mechanisms were identified to influence FSH β -encoding gene expression in recent years. Unsaturated long-chain fatty acids were shown to suppress the transcriptional activity of the *Fshb* gene in rats, and their effect is mediated via a –2824 to –2343bp region upstream of the promoter sequence (Moriyama *et al.* 2016). Bone morphogenetic protein 2 (BMP-2) is another factor that affects FSH expression via the induction of SMAD2/3 signaling through BMP type 1A receptor activation. It was suggested BMP2 action may involve similar signaling pathway as activins (Wang *et al.* 2014c).

Post-transcriptional regulation of FSH β -encoding gene expression

Whereas translational regulation of the FSH β -encoding gene and its associated pathways have been extensively studied for many years, the effects of post-transcriptional regulation and its implication to the overall FSH synthesis was not clarified until recent years. Recently, microRNAs (miRNAs) have emerged as key players in crosstalk between different gonadal signaling pathways and their activities can effectively inhibit or upregulate a process. They are now considered as important regulators of the hypothalamic–pituitary–gonadal axis. MiRNAs primarily act post-transcriptionally by destabilizing or degrading mRNA in the cytoplasm. They bestow tight control to the overall gene regulation in addition to maintaining mRNA cell specificity (Farh *et al.* 2005, Cui *et al.* 2006, Sood *et al.* 2006, Tsang *et al.* 2007, Lin *et al.* 2013). FSH regulates the production of a wide range of miRNAs that target genes encompassing diverse signaling pathways (Yao *et al.* 2009, 2010), but not much is known about how miRNAs affect the expression of FSH itself. Most of the studies investigating post-transcriptional regulation of FSH were done in stable cell lines or established primary cultures. To investigate miRNA-regulated production of the specific FSH β subunit *in vivo*, Wang and coworkers developed a *Dicer*-knockout mouse model and established that DICER-dependent miRNAs are indispensable for FSH β production (Wang *et al.* 2015).

One important control point of post-transcriptional regulation of FSH β -encoding mRNA by miRNAs is exerted at the level of GnRH regulation as shown by a targeted pathway analysis approach in porcine pituitary cell

Figure 1

Transcriptional regulation of FSH subunit-encoding genes. The three major players that regulate FSH subunit gene transcription include GnRH, activin–inhibin–follistatin and steroids. GnRH binds to GnRH receptors expressed on gonadotropes. MAPK/ERK phosphorylation is one of the major downstream pathways activated by GnRH. These signals are further transmitted by translocation and recruitment of key transcription factors EGR1, ATF3, SF-1 and MAPK pathway-catenin-dependent activation of c-Jun–c-Fos and AP-1 onto α -GSU and FSH β -encoding gene promoters. Estrogen, progesterone and testosterone can indirectly regulate FSH subunit-encoding gene transcription by suppressing GnRH. Testosterone and glucocorticoids can also directly regulate FSH β subunit-encoding gene transcription. Estrogen and testosterone can also regulate activin regulation of FSH β subunit-encoding gene transcription. Activins bind to activin receptor type II and phosphorylate ALK4/7 type 1 receptors. This heterotrimeric complex via a TAK1 pathway, phosphorylates receptor-specific SMAD 2/3 transducers, which complex with the phosphorylated common SMAD4 and bind to SMAD-binding elements on FSH β -encoding gene promoter. SMAD7 is an inhibitory SMAD that negatively regulates activin action. SMADs cooperatively bind with other co-factors including a key transcription factor, FOXL2 (not shown in the figure). Follistatin and inhibin bind activin and negatively regulate FSH β subunit-encoding gene transcription.

cultures (Ye *et al.* 2013). Besides identifying miRNAs that regulate GnRH induction of FSH β -encoding gene, this study identified 3 downregulated and 10 upregulated miRNAs that most likely are direct targets to the 3'-UTR region of FSH β -encoding mRNA. Recently, they demonstrated that miR-361-3p directly targets FSH β -encoding mRNA and negatively regulates its synthesis, providing further functional evidence that miRNA-mediated post-transcriptional modifications are involved in FSH production (Ye *et al.* 2017).

Another study identified that miR-132/212 are required for GnRH-stimulated expression of FSH β -encoding mRNA, and this induction involves the SIRT1-FOXO1 pathway. MiR-132/212 is also directly involved in post-transcriptional decrease of the sirtuin 1 (SIRT1) deacetylase (Lannes *et al.* 2015). Together, a regulatory loop that maintains high levels of miR-125b and low levels of miR-132 desensitizes the gonadotrope cells to GnRH stimuli, thereby disrupting the overall GnRH induction pathway (Lannes *et al.* 2016). Although the importance

of post-transcriptional regulation of FSH synthesis by miRNAs has been realized, the mechanisms that control the process needs further investigation.

In terms of FSH action, a genome-wide study investigating miRNA signatures in human granulosa cells demonstrated that miRNA-mediated post-transcriptional regulation might play a significant role in gonadotropin signaling and found a novel miRNA that had an intronic origin from the FSH receptor gene (Velthut-Meikas *et al.* 2013).

Post-translational regulation of FSH

Enzymatic and covalent modifications of the hormone-specific FSH β subunit polypeptide after its translation are critical steps in the assembly, synthesis and release of the biologically active FSH. The specific structural attributes and their molecular characteristics due to such modifications have been extensively investigated and reviewed (Combarnous 1992, Stockell Hartree & Renwick 1992, Stanton *et al.* 1996, Sood *et al.* 2006, Butnev *et al.* 2015). The major post-translational modifications of FSH β subunit resulting in the formation of different isoforms are N-glycosylation and sialylation, while the contribution of sulfation has no major biological effect on FSH secretion and or function (Bousfield & Dias 2011).

Regulation of FSH β N-glycosylation

The process of N-glycosylation is mediated by a multi-subunit oligosaccharyl transferase (OST) enzyme complex. The OST complex transfers a previously formed oligosaccharide from a dolichol pyrophosphate molecule to the newly formed FSH β chain in the endoplasmic reticulum and Golgi compartments (Baenziger & Green 1988, Butnev *et al.* 1996). N-acetyl-D-glucosamine precursors are co-translationally added to the conserved Asn²⁴ and/or Asn⁷ residues and are consequently converted to complex glycans by branching through addition of various sugar units. There could be one, two or no N-glycans attached onto FSH β , resulting in the formation of hypoglycosylated (FSH^{21/18}, missing one glycan chain on an Asn residue) or fully glycosylated (FSH²⁴, having branched glycans on both Asn residues) or de-glycosylated (FSH¹⁵, having no glycans on both Asn residues) FSH isoforms. Earlier studies have investigated the alterations in FSH biological activity due to differential glycosylation mainly through *in vitro* bioassays and radioimmunoassays. It was suggested that different

glycosylation variants have the ability to induce changes in receptor stability or conformation. Thus, activation or inhibition of a specific signal transduction pathway in target tissues could be a FSH glycosylation-dependent feature in FSH signaling (Zambrano *et al.* 1999). However, the overall conformational integrity of the glycans is not essential for effective receptor binding, but the rate of activity is altered following deglycosylation (Manjunath *et al.* 1982).

The state of FSH glycosylation is affected by various physiological conditions. The process of FSH glycosylation and glycan composition changes dynamically throughout the normal menstrual cycle (Wide & Eriksson 2013). Galactose-1-phosphate uridylyltransferase (GALT), an enzyme known to modulate production of different FSH glycoforms and its biological activity, was observed to have higher expression during the proestrous and estrous phases in rats (Daude *et al.* 1996), indicating a distinct role of estrous cycle in determining the formation of glycosylated species.

Calvo and coworkers indicated that deglycosylated forms might be less biologically active than their native fully glycosylated forms in granulosa cells (Calvo *et al.* 1986). Contrary to this finding, Bousfield and coworkers showed that hypoglycosylated FSH (hFSH^{21/18}) was up to 26 times more active than the fully glycosylated hFSH (hFSH²⁴). The enhanced activity of hFSH^{21/18} was suggested as a result of availability of more binding sites for hFSH^{21/18} than that for hFSH²⁴ in the FSH receptor (Bousfield *et al.* 2014). Further support came from an *in vitro* study that confirmed that hFSH^{21/18} was more effective in inducing cAMP production, CREB phosphorylation and PKA activity (Jiang *et al.* 2015). The first *in vivo* study by Wang and coworkers investigated bioactivities of the different FSH glycoforms, using *Fshb*-null mice in a pharmacological rescue approach (Wang *et al.* 2016a). This study identified that recombinant hFSH^{21/18} and hFSH²⁴ glycoforms have identical bioactivities when injected into immature *Fshb*-null mice (Wang *et al.* 2016a). They also showed that N-glycosylation of FSH β is needed for its assembly with the α -subunit to form the functional FSH heterodimer in mouse pituitaries, and the FSH β glycans are determinants of FSH secretion and biological activity *in vivo* (Wang *et al.* 2016b). Previous *in vitro* studies have also shown that N-linked glycan structures on FSH affect gene expression, thus regulating production of growth factors, proteins and hormones that are required for ovarian granulosa cell functions (Loreti *et al.* 2013).

The differential glycosylation of hFSH β was proposed to be due to selective inhibition of the oligosaccharyl transferase enzyme activity (Walton *et al.* 2001, Bousfield *et al.* 2007). But how the selective glycosylation of FSH β subunit is controlled by OST activity, while the α -subunit undergoes full glycosylation in the same cellular compartment is yet to be understood. It may be that different OST isoforms may be involved in the process. OST isoforms in mammals differ in the characteristics of their catalytic subunit (Kelleher *et al.* 2003), and it is observed that OST containing the STT3A subunit is involved in the cotranslational process of N-glycosylation, while the STT3B subunit is associated with the post-translational modifications (Ruiz-Canada *et al.* 2009).

After the highly conserved N-glycosylation in the ER, the folded proteins are translocated to Golgi where diversity of the glycan forms are generated, and the process of glycan branching is a crucial contributor of this diversity. Glycan branching is mediated by a family of N-acetylglucosamine (GlcNAc) transferases. A single gene encodes GlcNAc transferases I, II, and III in human and mouse, while the two isoforms of both GlcNAc transferases IV and V are encoded by separate genes (Bousfield & Dias 2011). Loss of GlcNAc transferase activity was found to be either embryonic lethal (Ioffe & Stanley 1994) or contributes to various reproductive disorders in mice (Wang *et al.* 2001, Williams & Stanley 2009). The high molecular weight tri- and tetra-antennary glycans are synthesized mainly by GlcNAc transferases IV and V.

Regulation of FSH β sialylation

FSH β sialylation involves post-translational modification resulting in the addition of sialic acid units to the end of its oligosaccharide chain. FSH contains predominantly sialylated oligosaccharides, unlike LH which has more sulfated oligosaccharides. It was speculated that FSH-bound sialic acid residues may aid in targeted translocation to separate secretory granules, thereby providing a regulatory mechanism distinct from other gonadotrophins (Baenziger & Green 1988). *In vitro* bioassay analysis had previously indicated important role of sialic acid in biological activities of equine FSH (Aggarwal & Papkoff 1981). Since number of sialic acid contributes to the overall acidic nature of the FSH β subunit, sialylation is thought to be responsible for the regulation of the rate of molecular interactions that requires charge specificity. The less acidic or sialylated FSH isoforms may contribute

to different or unique hormonal effects at the target cell level (Timossi *et al.* 2000). Less sialylated FSH-induced increased cAMP release, tissue-type plasminogen activator (tPA) enzyme activity, estrogen production, along with upregulating cytochrome P450 aromatase and tPA mRNA expression (Barrios-De-Tomasi *et al.* 2002). On the other hand, more sialylated glycoforms stimulated an increased expression of alpha-inhibin subunit mRNA, indicating a possible post-translationally controlled feedback inhibitory mechanism mediated by the extent of FSH charge variation. More acidic mixtures of FSH isoforms, which have slower clearance rate than a less acidic mixture, were shown to facilitate follicular maturation in the ovary and stimulate estrogen production in sheep (West *et al.* 2002).

Other than enzyme-mediated post-translational modification of FSH glycans, GnRH and gonadal steroids can also affect the synthesis and release of different FSH isoforms. GnRH is known to induce glycosylation, whereas estradiol aids in the GnRH-induced glycosylation process, suggesting an indirect GnRH-driven FSH regulation at the post-translational level. Synthesis of FSH isoforms with differentially linked sialic acids is hormonally regulated in male rats (Ambao *et al.* 2009). In addition, testosterone also increases sialylation (Wilson *et al.* 1990). Progesterone is known to influence pituitary glycosylation, consequently altering the relative proportions of FSH isoforms in cattle (Perera-Marin *et al.* 2008).

After ovarian failure that normally occurs as a function of aging, more acidic FSH becomes dominant and significantly detectable in older premenopausal women (Thomas *et al.* 2009). A change in FSH isoform abundance, toward less acidic molecules was also observed in cows with ovulatory follicles compared to those with atretic follicles, and this shift in FSH isoforms is suggested to decide the capability for producing a preovulatory estradiol rise (Butler *et al.* 2008). Factors like age, sex and reproductive state can also influence the formation of the type of the FSH isoforms in sheep pituitary (Moore *et al.* 2000).

Regulation of FSH secretion

FSH is constitutively secreted from the gonadotrope cells via a complex multilayered regulatory process. Moreover, longer half-life in circulation and molecular heterogeneity makes detection of FSH secretory patterns more difficult through peripheral hormone measurements. The regulation of FSH secretion appears to be dominated by

Figure 2

Regulation of FSH secretion. GnRH is secreted in pulses from the hypothalamus. Its secretion is regulated by multiple neuropeptides including PACAP and Kisspeptin. GnRH positively regulates FSH synthesis from pituitary. FSH binds to gonadal cell receptors and produce steroids, which directly or indirectly act at the level of the pituitary or hypothalamus, respectively. Both locally produced factors within gonadotrophs such as activins, inhibins and follistatin and other peptides such as PACAP and Kisspeptin whose receptors are expressed by gonadotrophs, regulate GnRHR and FSH β subunit-encoding genes. Gonads are also an abundant source of activins and inhibins, which act like typical endocrine factors to regulate FSH secretion from pituitary. FSH is mostly constitutively secreted and its synthesis is tightly linked to its secretion.

factors controlling inhibition of both its synthesis and release. This process includes three major aspects: GnRH signaling, and activin–inhibin–follistatin pathways and control by gonadal steroids (Fig. 2).

GnRH-mediated regulation of FSH secretion

Only low levels of GnRH are sufficient for the stimulation and maintenance of FSH secretion. FSH release from gonadotrophs, unlike that of LH, is tightly associated with its rate of synthesis (McNeilly 1988). Various regulatory neuropeptides and hypothalamic factors are thought to be responsible for GnRH-mediated FSH secretion. Orexin A, synthesized by a small population of cells in the hypothalamus, was found to significantly inhibit GnRH-stimulated FSH release from rat pituitary cells. This neuropeptide was shown to modify GnRH sensitivity of gonadotrophic cells, and its effect may be age and estrogen dependent (Martynska *et al.* 2014). Pituitary adenylyl cyclase-activating polypeptide (PACAP) is known to facilitate GnRH-mediated secretion of FSH from sheep pituitary gonadotrophs, but the increase in release is only seen at concentrations higher than normal physiological limit (Sawangaroen *et al.* 1997). GnRH itself does not directly regulate FSH at the level of secretion, but it regulates mostly at the level of FSH synthesis (McNeilly 1988).

Activin–inhibin–follistatin-mediated regulation of FSH secretion

Ling and coworkers first identified activin as a FSH-releasing factor and coined the name to signify its opposing biological activity compared to inhibin (Ling *et al.* 1986). Inhibin has structural organization homologous to that of transforming growth factor-beta (TGF- β). Earlier investigations on activin–inhibin-mediated secretion of FSH were mainly performed in rodent primary pituitary cultures. Gonadotrophic secretion of activin B was suggested to provide an autocrine signal that selectively modulated FSH secretion in rat pituitary cells cultures, while FSH inhibitory actions of inhibin and follistatin was attributed to their interference with endogenous activin B or its activity (Corrigan *et al.* 1991). It was also previously reported that follistatin suppresses FSH secretion in a highly specific manner since it shows no demonstrable effect on the release of other pituitary hormones (Ying *et al.* 1987). Moreover, follistatin-treated pituitary cells showed significantly less depletion of intracellular FSH content than those treated with inhibin. This suggests unlike inhibin, follistatin acts primarily by suppressing FSH secretion. The mode of follistatin action consists of binding and neutralization of both activin A and B forms (Schneyer *et al.* 2003), and this specific binding to activin is decisive in determining follistatin's differential biological activity (Sidis *et al.* 2002). It was later demonstrated that inhibin immunization with anti-inhibin serum in

diestrous rats also significantly increased FSH secretion *in vivo* (Gordon *et al.* 2010).

Regulation of FSH secretion by gonadal steroids

Mechanisms of gonadal steroid hormone regulated FSH secretion are mostly interweaved with both GnRH-mediated and activin–inhibin-regulated pathways, indicating the complexity and selective interdependency of these processes. In rodents, estrous cycle plays an important role in dictating this steroid hormone regulated FSH secretion. It was noted that anti-progestins RU486 and ZK98299 affected levels of serum FSH and FSH β mRNA in a similar manner during proestrus, while they showed divergent patterns on estrus indicating that the active functional state of progesterone receptor/transcriptional activation complex is different during the two cyclic phases (Ringstrom *et al.* 1997). A study also indicated that estrogen and inhibin both differentially modulate the estrus stage-dependent increased secretion of FSH in bovine pituitary cells (Lane *et al.* 2005).

It was also shown that the suppression of both basal and activin-mediated FSH secretion takes place in an estrogen-dependent process (Szabo *et al.* 1998). Progesterone receptors, upon induction by estradiol, respond to activin-induced signal transduction to regulate FSH release. A study in ovine pituitary cells reported that differential effects of estradiol on FSH secretion in ovine pituitary cells may be indirectly mediated by activin (Baratta *et al.* 2001). An *in vivo* study on rats confirmed the regulation of FSH secretion by estrogen and inhibins and identified estradiol-17 beta as the major candidate mediating the mechanism (Herath *et al.* 2001). The negative estrogen feedback was associated with increased levels of both inhibin isoforms in plasma, while inhibin A seems to be the dominant species during the initiation of the process. The mechanism of estrogen suppression of FSH release *in vivo* was investigated in pre-pubertal mice in a recent study, which indicated that the process takes place via the activation of estrogen receptor- α in kisspeptin neurons directly affecting GnRH release (Dubois *et al.* 2016). Other than estrogen, progesterone and corticosterone, testosterone is also known to stimulate the release and maintain intracellular levels of FSH by the activation of the androgen receptor (directly or as dihydrotestosterone) and conversion to estradiol or activation of estrogen receptors (Hiipakka & Liao 1998, McPhaul & Young 2001). The steroid hormone actions are

mediated by activin, which involves a tightly regulated activin/follistatin autocrine–paracrine loop (Bohnsack *et al.* 2000).

Other factors regulating FSH secretion

Several other molecular factors, independently or in association with the above described pathways, contribute to the complex regulation of FSH secretion. One of them is corticosterone, which stimulates selectively FSH release (Kilen *et al.* 1996). Bone morphogenetic protein-4 (BMP-4) exerts inhibitory effects on FSH release, via the induction of Smad1 phosphorylation and activation of the BMP signaling pathway (Faure *et al.* 2005). BMP-4 blocks activin stimulation of FSH release in addition to increasing the 17 β -estradiol-mediated suppression of FSH secretion. Adiponectin, a protein involved in glucose regulation and fatty acid catabolism, is another factor that increases FSH release from the pituitary gonadotrophs (Kiezun *et al.* 2014). This establishes a new crosstalk between the glucose-fatty acid metabolic pathways and the reproductive axis.

Roper and coworkers recently identified synaptotagmin 9 (synt-9), a Ca²⁺ sensor protein associated with exocytosis in neuroendocrine cells, as a regulator of FSH secretion *in vivo* (Roper *et al.* 2015). Interestingly, they found that synt-9 and FSH were co-localized in pituitaries of female but not male mice. Accordingly, loss of synt-9 reduced FSH secretion only in females, indicating a sex-specific regulation of FSH. A population study on human subjects reported that adrenocorticotrophic hormone (ACTH) regulates FSH release. This study identified a novel pathway of gonadotropin secretion mediated by the adrenal cortex (Aleknaviciute *et al.* 2016). Ghrelin, a neuropeptide involved in the regulation of physiological energy balance, was also found to influence FSH secretion in pre-pubertal sheep (Wojcik-Gladysz *et al.* 2016). The identification of novel factors from such diverse physiological pathways indicates the complexity of FSH regulation. It further substantiates the idea that various signaling networks, related or unrelated to the direct regulation of the reproductive axis, act in parallel to maintain FSH levels.

Regulation of FSH action

The actions of FSH in regulating the reproductive axis have been extensively investigated over the years (Loraine & Schmidt-Elmendorff 1963, Simoni *et al.* 1999, Howles

2000, Zafeiriou *et al.* 2000, Sairam & Krishnamurthy 2001, Smitz *et al.* 2016). FSH binds and activates, a 7 transmembrane (7TMR) domain containing FSH receptor (FSHR) expressed in granulosa cells in ovaries and Sertoli cells in testes (Simoni *et al.* 1997). Inactivating either *Fshb* or *Fshr* leads to consistent reproductive defects (Matthews *et al.* 1993, Layman *et al.* 1997, Huhtaniemi *et al.* 2006) and based on its physiological target, FSH controls distinct biological responses like cell proliferation, differentiation, steroidogenesis, metabolism and apoptosis (Dias *et al.* 2010) (Fig. 3).

Regulation of FSH functions mediated by FSHR

For several decades, the canonical Gs/cAMP/PKA pathway has been considered as the major mechanism by which FSH exerts its actions within target cells (Dattatreya *et al.* 1987). However, in recent years, it has been recognized that FSH binding to its receptor also induces several other signaling pathways, adding to the growing complexity (Gloaguen *et al.* 2011). Activation of protein kinase B (PKB/Akt) was identified as an alternative response of FSH-FSHR binding (Zelevnik *et al.* 2003), which was reported

Figure 3

A summary of different signaling mechanisms that mediate FSH actions in target cells. FSH binds to G-protein-coupled seven transmembrane -spanning FSHRs expressed on target cells. This leads to the activation of a battery of signaling pathways depending on the developmental and physiological context. In the female, FSH mainly acts to regulate ovarian folliculogenesis and steroidogenesis. Recently, extragonadal actions of FSH mediated via FSHRs, have been identified, particularly in osteoclasts in female rodent bones. These observations have implications for understanding and treating bone loss in post-menopausal women. In the male, FSHRs are expressed on Sertoli cells in the testis. FSH regulates pre-pubertal proliferation and maturation of Sertoli cells. Proper maturation of Sertoli cells is essential for maintaining optimal spermatogenesis. Other extragonadal functions of FSH have also been proposed but these are yet to be rigorously tested.

to be a cAMP-dependent and PKA-independent pathway (Gonzalez-Robayna *et al.* 2000, Meroni *et al.* 2002). This involves an exchange protein (EPAC) directly activated by cAMP. Wayne and coworkers later demonstrated the significance of EPACs in mediating biological activities of FSH (Wayne *et al.* 2007). A more recent study suggests that FSH-stimulated ERK activation in granulosa cells involves PKA-dependent inactivation of MAP kinase phosphatase (3MKP3) (Donaubauer *et al.* 2016). FSH-responsive genes are also regulated by forkhead box O1 (FOXO1) protein in ovarian granulosa cells via the phosphatidylinositol-3 kinase/AKT (Herndon *et al.* 2016). Insulin-like growth factor-2 (IGF-2) expression is also regulated by FSH through the AKT-dependent pathway (Baumgarten *et al.* 2015). Further, IGF-1 and FSH signaling pathways are shown to interact in granulosa cells both *in vitro* and *in vivo* (Zhou *et al.* 2013, Stocco *et al.* 2017).

FSHR can couple with other G protein subtypes. FSHR was shown to activate pertussis toxin-sensitive pathways upon binding certain hormone variants or depending upon the specific developmental stage of target cells (Arey *et al.* 1997, Crepieux *et al.* 2001). FSHR also activates the inositol trisphosphate (IP3) signaling pathway (Quintana *et al.* 1994) and interacts directly with G_{α_q} subunit in granulosa cells (Escamilla-Hernandez *et al.* 2008). In an alternate signaling mechanism observed in Sertoli cells, the FSH-induced IP3 response was explained via functional coupling of FSHR and tissue transglutaminase (G_{α_h}), which results in PLC δ activation and IP3 accumulation (Lin *et al.* 2006).

Other than the well-known heterotrimeric G-proteins, G protein-coupled receptor kinases (GRKs) and β -arrestins are two other classes of proteins shown to interact specifically with FSHRs upon FSH induction. GRKs and β -arrestins regulate FSHR stimulation by controlling selective sensitization, internalization and recycling of FSHR (Nakamura *et al.* 1998, Troispoux *et al.* 1999, Reiter *et al.* 2001, Kishi *et al.* 2002, Marion *et al.* 2002, 2006, Krishnamurthy *et al.* 2003, Piketty *et al.* 2006). But over last few years, the spectrum of functions performed by β -arrestins has expanded. They also act as signal transducers in a G protein-independent manner at different 7TMRs (Lefkowitz & Shenoy 2005, Reiter & Lefkowitz 2006). Although only FSHR-mediated β -arrestin-dependent and G protein-independent activation of ERK and rpS6 has so far been identified as the effector mechanism, it could be predicted that β -arrestins are associated with the G protein-independent activation of a wide array of differential signaling pathways downstream of the FSHR.

β -Arrestins are known to function as multifunctional scaffolds interacting with several proteins, thereby facilitating the phosphorylation of numerous intracellular targets at other transmembrane receptors (Xiao *et al.* 2007, Whalen *et al.* 2011). The adaptor protein phosphotyrosine interacting with PH domain and leucine zipper 1 (APPL1) was reported to directly bind FSHR, consequently triggering downstream signaling cascades. APPL1 was originally suggested to interact with the first intracellular FSHR loop and APPL1 induces FSH-dependent PI3K signaling (Nechamen *et al.* 2004). A recent study showed that FSH-stimulated activation of the inositol-phosphate calcium pathway requires APPL1-FSHR interaction (Thomas *et al.* 2011). PI3K pathway is also induced by the members of the Src family of kinases in granulosa cells (Wayne *et al.* 2007). FSH-induced activation of ERK pathway is mediated by Src proteins in granulosa and Sertoli cells (Crepieux *et al.* 2001, Cottom *et al.* 2003). FSH also induced epidermal growth factor receptor (EGFR) autophosphorylation in granulosa cells via Src activation (Cottom *et al.* 2003, Wayne *et al.* 2007). This suggests an important role of EGFR transactivation in relaying the FSH signals in the target cells. In addition, EGRF inhibition reduced the ability of FSH to stimulate CDK4 activation and ERK/Akt phosphorylation in different model systems (Cottom *et al.* 2003, Andric & Ascoli 2006, Shimada *et al.* 2006, Yang & Roy 2006, Wayne *et al.* 2007). FSH also regulates the initiation of germ cell mitosis/meiosis in embryonic chicken through the involvement of progesterone and upregulation of miR181a. This miRNA inhibits meiotic initiation by suppressing the nuclear receptor subfamily 6 group A member 1 (NR6A1) transcript (He *et al.* 2013).

Mouse models for studying FSH actions *in vivo*

The development of transgenic mouse models contributed to major advancements in the field of reproduction research. Several mouse models were generated that largely facilitated our understanding of how FSH acts in normal reproductive physiology and under pathological conditions. The models belong to two categories. In the gain-of-function, reporter gene (e.g., transgenes encoding subunits of a protein or CRE recombinase enzyme) expression is driven by specific promoter sequences. In the loss-of-function model (knockout, KO), mutations at a target locus are first produced in embryonic stem cells (ES) followed by propagation of the resulting mutant allele through germline (Kumar *et al.* 2009). Multiple

KO mutations could be combined and an intercross of KO model with a gain-of-function model results in a genetic rescue model. Cell- or tissue-specific deletion of a gene is of interest, since such a technology allows us to investigate molecular mechanisms in a tissue of interest selectively, when global null mutations result in undesired or even lethal phenotypes. LoxP-flanked genes of interest combined with CRE-expressing transgenic lines as drivers are used to achieve such tissue-, cell-specific deletions (Schmidt-Supprian & Rajewsky 2007, Bouabe & Okkenhaug 2013, Deng 2014).

A transgenic mouse model overexpressing the human *CGA* gene was generated, which did not show any major reproductive abnormalities (Fox & Solter 1988). Kumar and coworkers developed the first transgenic mouse model for FSH. They demonstrated gonadotroph-specific expression of a 10kb human *FSHB* transgene in mouse pituitaries (Kumar *et al.* 1992). Overexpression of the human FSH β subunit did not result in any overt phenotypes in female transgenic mice. Transgenic males, however, showed a marginal increase in testis weight without any major male reproductive consequences (Kumar *et al.* 1992). This mouse model was further used to demonstrate differences in steroid hormone regulation between mouse *Fshb* and human *FSHB* gene expression (Kumar & Low 1993, 1995) and GnRH regulation (Kumar & Low 1995). This model also served as a genetic platform to further identify and narrow down regulatory elements controlling human *FSHB* expression *in vivo* (Kumar *et al.* 2006).

A bi-transgenic human FSH-expressing model was developed by a genetic intercross between two independent transgenic lines. One line expressed a human *CGA* mini-gene and another the *FSHB* gene. Both the transgenes were expressed from a mouse metallothionein-1 promoter. This ectopic expression of human FSH dimer was achieved at low and very high levels (Kumar *et al.* 1999). The low level human FSH-expressing mice developed normally, do not display any abnormalities and are fertile. The very high level human FSH-expressing male mice were infertile, displayed hyperandrogenemia and consequently enlarged seminal vesicles but spermatogenesis looked qualitatively normal in testes of these mice (Kumar *et al.* 1999). The transgenic female mice expressing very high levels of human FSH were infertile, their ovarian histology was normal initially up to 2 weeks, and several abnormalities were noticed by 3 weeks and beyond. In transgenic mice at 6 weeks of age, the ovaries contained many hemorrhagic follicles with totally disrupted folliculogenesis. At this age, serum levels of estrogen, progesterone, testosterone and activins were elevated. Very few (~5%) transgenic female

mice survived and died by 13 weeks of age presumably secondary to urinary bladder and kidney defects (Kumar *et al.* 1999). Thus, female mice ectopically expressing high levels of human FSH demonstrate at least some features of polycystic ovarian syndrome in women.

Allan and coworkers developed another ectopic human FSH dimer expressing line of mice, in which the human FSH subunit-encoding cDNA transgenes were engineered in tandem and targeted to liver using a rat insulin II promoter (Allan *et al.* 2001). These transgenic mice were later intercrossed with *hpg* mice and maintained on the *hpg* genetic background (*hpg*; *hFSH*⁺). Because of a naturally occurring mutation in the *Gnrh* gene, *hpg* mice do not produce GnRH and hence gonadotropins and ovarian steroids and are infertile (Allan *et al.* 2001). Thus, this genetic approach allowed the investigators to test the effects of ectopically expressed human FSH in the absence of LH and gonadal steroids. Male transgenic mice on *hpg* background, with human FSH at levels >1IU/L showed partial rescue of the testis and spermatogenesis phenotypes. Testis size increased and histological analysis revealed that spermatogenesis progressed until early post-meiosis (Allan *et al.* 2001, Haywood *et al.* 2003), similar to the phenotypes observed in *Lhb*-null mice (Ma *et al.* 2004). When supplemented with testosterone, spermatogenesis was fully restored in these *hpg*; *hFSH*⁺ mice. Female *hpg*; *hFSH*⁺ mice also showed rescue; the ovarian follicle reserve increased and ovarian histology demonstrated many antral follicles and serum inhibin levels elevated. Surprisingly, *hFSH*⁺ transgenic mice alone (not on *hpg* background) by ~6 months of age showed accelerated aging leading to premature ovarian failure (Allan *et al.* 2001).

Because *hpg* mice lack both FSH and LH as a result of loss of functional GnRH, to study the *in vivo* roles of exclusively FSH, a loss-of-function mouse model for FSH action was generated using embryonic stem cell technology (Kumar *et al.* 1997). *Fshb*-null mice developed normally and demonstrated reproductive phenotypes. *Fshb*-null males were fertile despite displaying reduced testis size as a result of reduced Sertoli cell- and germ cell-carrying capacity (Wreford *et al.* 2001), reduced sperm number and motility (Kumar *et al.* 1997). *Fshb*-null females displayed hypoplastic ovaries and uterine horns. Ovarian histology showed a preantral stage block in folliculogenesis, and no evidence of corpora lutea indicating that these null mice were anovulatory (Kumar *et al.* 1997). However, in a superovulation protocol, when injected with exogenous hormones, these null female mice responded and released comparable number of oocytes similar to control mice (Kumar *et al.* 1997). Thus, FSH responsiveness is retained

in these null female mice in the absence of FSH ligand from birth. Subsequent studies with *Fshb*-null females showed that FSH regulates transzonal projection-mediated communication between granulosa cells and oocytes (Combelles *et al.* 2004), gap junction proteins between granulosa cells (El-Hyek & Clarke 2015, Clarke 2018) and epidermal growth factor receptor expression in granulosa cells to prime the follicles for ovulation prior to LH action (El-Hayek *et al.* 2014).

Knockout mice lacking *Fshr* gene display defects in reproductive function in both male and female mice,

similar to those seen in mice lacking FSH (Kumar *et al.* 1997, Dierich *et al.* 1998, Abel *et al.* 2000). *Fshb* genetic rescue, activin, inhibin and follistatin knockouts, FSH glycosylation mutants and FSH rerouted transgenic models were used in various studies to investigate the entire spectrum of FSH actions *in vivo* (Matzuk *et al.* 1992, 1995, Guo *et al.* 1998, Kumar *et al.* 1998, Jorgez *et al.* 2004, Sandoval-Guzman *et al.* 2012, Abel *et al.* 2014, Wang *et al.* 2014c). Recently, these models were reviewed in detail (Kumar 2016) and summarized in Table 1. Inactivating mutations in human *FSHB* and *FSHR* are although rare,

Table 1 Mouse models for FSH synthesis, secretion and action.

Model	Phenotypes	Reference
<i>Cga</i> transgenic	Cell-specific expression and regulation of the human alpha-subunit transgene in the pituitary. No detectable expression in placenta	Fox & Solter (1988)
<i>Cga</i> knockout	A loss-of-function mutation. Hypogonadism and hypothyroidism	Kendall <i>et al.</i> (1995)
Human <i>FSHB</i> transgenic	Human FSH β -overexpression in pituitary gonadotropes. Increased testis weight in males. No overt phenotypes in females	Kumar <i>et al.</i> (1992)
<i>MT-CGA/MT-FSHB</i> bi-transgenic	Multiple reproductive defects including hemorrhagic and cystic ovaries in females. Males infertile with enlarged seminal vesicles and elevated serum testosterone	Kumar <i>et al.</i> (1999)
<i>Fshb</i> knockout	Males fertile with decreased testis size. Females infertile with a per-antral stage block in folliculogenesis. Increased bone density	Kumar <i>et al.</i> (1997)
<i>Fshb</i> genetic rescue	Testis size, sperm number, and motility defects in <i>Fshb</i> -null males rescued. Folliculogenesis resumed normally in females	Kumar <i>et al.</i> (1998)
<i>FSHB</i> rerouted transgenic	<i>Fshb</i> -null mice rescued by rerouted FSH. Enhanced ovarian follicle survival, increase in ovulation number, and prolonged reproductive lifespan in females	Wang <i>et al.</i> (2014a)
<i>FSHB</i> glycosylation mutant transgenic rescue	The double N-glycosylation mutant (Asn ^{7Δ} Asn ^{24Δ}) transgene fails to rescue <i>Fshb</i> -null mice	Wang <i>et al.</i> (2016a)
Human <i>FSH/hpg</i> transgenic rescue	Males showed increased testis weight up to 5-fold. Females exhibited enlarged ovaries and a strong FSH dose-dependent increase in serum inhibin B levels	Allan <i>et al.</i> (2001)
<i>Fshr</i> knockout	Phenocopy <i>Fshb</i> -null mice. Males fertile but with reduced testes size. Females infertile	Dierich <i>et al.</i> (1998), Abel <i>et al.</i> (2000)
Activating <i>Fshr</i> transgenic (D580H)	Hemorrhagic cysts, accelerated loss of small follicles, increased gonadotropins, prolactin and elevated estrogen	Peltoketo <i>et al.</i> (2010)
<i>Inha</i> knockout	Development of gonadal stromal tumors, elevated levels of serum FSH, activins and estradiol	Matzuk <i>et al.</i> (1992)
<i>Inha/Fshb</i> double knockout	Slow-growing and less hemorrhagic testicular tumors in males and ovarian tumors in females, and with minimal cachexia	Kumar <i>et al.</i> (1999)
<i>Acvr2a</i> knockout	Suppressed FSH production and defects in reproductive performance. Males subfertile or infertile and exhibit male sexual behavior defects; females with parturition defects	Matzuk <i>et al.</i> (1995), Ma <i>et al.</i> (2005)
<i>MT-Follistatin</i> transgenic	Multiple reproductive defects. Marginally elevated FSH in on line with widespread expression of the FS transgene	Guo <i>et al.</i> (1998)
<i>Smad3/Smad4</i> gonadotroph-specific knockout	Phenocopy of <i>Fshb</i> -null mice	Li <i>et al.</i> (2017)
<i>Foxl2</i> knockout	Impaired FSH synthesis and secretion, ovarian function	Schmidt <i>et al.</i> (2004), Uda <i>et al.</i> (2004), Justice <i>et al.</i> (2011)
<i>Foxl2</i> gonadotrope-specific knockout	Impaired FSH synthesis and fertility	Tran <i>et al.</i> (2013)
<i>Smad4/Foxl2</i> double knockout	Phenocopy of <i>Fshb</i> -null mice	Fortin <i>et al.</i> (2014)

they have been reported (Huhtaniemi & Themmen 2005, Narayan *et al.* 2018). While mouse models lacking *Fshb* are somewhat discordant, those lacking *Fshr* mostly phenocopy human mutations in the corresponding gene (Kumar 2016).

Extragonadal actions of FSH

The central dogma of classical FSH actions in gonads has been challenged in the past decade by studies that demonstrated a direct involvement of FSH in bone physiology (Sun *et al.* 2006). FSH levels increase sharply in contrast to declining estrogen levels as observed in post-menopausal women with osteoporosis. A direct effect of FSH on the skeletal system was discovered using *Fshb*- and *Fshr*-null mice, which have increased bone density (Sun *et al.* 2006). $G_{i2\alpha}$ -coupled FSH receptors were identified in osteoclasts and their precursors. An increase in osteoclast formation and function was demonstrated by an FSH-FSHR-dependent activation of MEK/Erk, Akt and NF-KB pathways, suggesting a positive correlation of circulating FSH with hypogonadal bone loss (Sun *et al.* 2006). FSH was also shown to regulate FSHR-induced alveolar bone loss in rats by an estrogen-independent process (Liu *et al.* 2010). The mechanism of FSH-induced increase alveolar bone loss was addressed in a recent study that showed that the FSH effect was mediated by upregulation of the cyclooxygenase-2 (COX-2) protein and the process involves Akt, Erk and p38 signaling pathways (Zhu *et al.* 2016a). A new concept advocated that a reciprocal cross signaling operates between FSHR signaling by FSH and bone morphogenetic protein-9 (BMP-9)-induced activation of BMP/Smad signaling in mouse embryonic fibroblasts. This study identified the cross signaling between FSH and BMP-9 promoted osteogenic differentiation (Su *et al.* 2017). Controversy exists with regard to FSH actions on bone (Kumar 2018) as data obtained using both mice and humans, contradict the original observations made by Sun *et al.* (2006).

In addition to its previously discussed functions in skeletal system, FSH was reported to act on the endothelial cells of human umbilical cord and monocytes (Robinson *et al.* 2010, Cannon *et al.* 2011, Stille *et al.* 2014b). FSH receptors have been identified in female reproductive tract and the developing placenta, and the functional relevance on this finding was confirmed by the observation that *Fshr*-knockout mice exhibit feto-placental defects (Stille *et al.* 2014a). Low levels of *Fshb* expression was also detected in various non-ovarian tissues, maternal uterine decidua, placenta and uterine myometrium in pregnant women.

Tumor blood vessels were also shown to express FSHRs (Radu *et al.* 2010) and FSH action has been implicated in endometriosis (Ponikwicka-Tyszko *et al.* 2016). Data are also available on FSH action on prostate tumors (Ide *et al.* 2013, Siraj *et al.* 2013, Zhu *et al.* 2016b). Finally, a blocking antibody against FSH shown to be efficacious in reducing white fat accumulation and conversion to brown fat accompanied by mitochondrial biogenesis in ovariectomized mice (Liu *et al.* 2017). The biochemical identity and the key downstream components of extragonadal FSH receptors are not clear. At least in mouse bone osteoclasts and adipocytes, FSH signaling pathways appear to be different and involve non-cAMP-mediated effects (Sun *et al.* 2006, Liu *et al.* 2017). The physiological relevance of FSH actions in at least some extragonadal tissues was challenged recently (Stelmaszewska *et al.* 2016), yet to be rigorously tested and may require development of novel genetic models (Kumar 2018).

Conclusion

Over the past several decades, studies on FSH have identified the molecular mechanisms for its overall regulation. Starting from signals mediating the initial synthesis to those needed for exerting successful biological actions, every step of FSH regulation is under tight control. Thus, the regulation FSH is highly complex and multilayered. Crosstalk between various signaling pathways modulate specific steps and further adds up to the complexity. As discussed in this review, novel findings related to the transcriptional, translational, post-translational and functional regulatory mechanisms validate that FSH plays a more comprehensive role in controlling various physiological functions than just being classified as a reproductive effector.

Appreciation of diverse functions of FSH and their regulation would be instrumental in developing effective therapies related to both reproductive disorders and other pathological conditions known to be directly or indirectly affected by FSH. For example, with the new understanding that FSH may be a key player in age-related bone loss, effective estrogen and related therapies for bone loss treatment could be implemented. One concept is to develop novel antagonists for both FSH and its receptor. Our knowledge of novel FSH functions in extragonadal is currently limited. More comprehensive investigations are needed to decipher the underlying molecular mechanisms that interweave FSH regulation across different physiological systems. A deeper understanding of such mechanisms of the overall FSH regulation will

facilitate the development of novel hormonal therapies in the coming decade.

Declaration of interest

The authors declare that there is no conflict of interest that could be perceived as hindering the impartiality of this review.

Funding

Research in the Kumar Laboratory is supported in part by the NIH grants CA166557, AG029531, AG056046, HD081162 and The Makowski Endowment Funds.

References

- Abel MH, Wootton AN, Wilkins V, Huhtaniemi I, Knight PG & Charlton HM 2000 The effect of a null mutation in the follicle-stimulating hormone receptor gene on mouse reproduction. *Endocrinology* **141** 1795–1803. (<https://doi.org/10.1210/endo.141.5.7456>)
- Abel MH, Widen A, Wang X, Huhtaniemi I, Pakarinen P, Kumar TR & Christian HC 2014 Pituitary gonadotrophic hormone synthesis, secretion, subunit gene expression and cell structure in normal and follicle-stimulating hormone beta knockout, follicle-stimulating hormone receptor knockout, luteinising hormone receptor knockout, hypogonadal and ovariectomised female mice. *Journal of Neuroendocrinology* **26** 785–795. (<https://doi.org/10.1111/jne.12178>)
- Aggarwal BB & Papkoff H 1981 Relationship of sialic acid residues to *in vitro* biological and immunological activities of equine gonadotropins. *Biology of Reproduction* **24** 1082–1087.
- Aleknaviciute J, Tulen JH, Timmermans M, de Rijke YB, van Rossum EF, de Jong FH & Kushner SA 2016 Adrenocorticotrophic hormone elicits gonadotropin secretion in premenopausal women. *Human Reproduction* **31** 2360–2368. (<https://doi.org/10.1093/humrep/dew190>)
- Allan CM, Haywood M, Swaraj S, Spaliviero J, Koch A, Jimenez M, Poutanen M, Levallet J, Huhtaniemi I, Illingworth P, *et al.* 2001 A novel transgenic model to characterize the specific effects of follicle-stimulating hormone on gonadal physiology in the absence of luteinizing hormone actions. *Endocrinology* **142** 2213–2220. (<https://doi.org/10.1210/endo.142.6.8092>)
- Ambao V, Rulli SB, Carino MH, Console G, Ulloa-Aguirre A, Calandra RS & Campo S 2009 Hormonal regulation of pituitary FSH sialylation in male rats. *Molecular and Cellular Endocrinology* **309** 39–47. (<https://doi.org/10.1016/j.mce.2009.05.002>)
- Andric N & Ascoli M 2006 A delayed gonadotropin-dependent and growth factor-mediated activation of the extracellular signal-regulated kinase 1/2 cascade negatively regulates aromatase expression in granulosa cells. *Molecular Endocrinology* **20** 3308–3320. (<https://doi.org/10.1210/me.2006-0241>)
- Arey BJ, Stevis PE, Deecheer DC, Shen ES, Frail DE, Negro-Vilar A & Lopez FJ 1997 Induction of promiscuous G protein coupling of the follicle-stimulating hormone (FSH) receptor: a novel mechanism for transducing pleiotropic actions of FSH isoforms. *Molecular Endocrinology* **11** 517–526. (<https://doi.org/10.1210/mend.11.5.9928>)
- Attisano L & Wrana JL 2002 Signal transduction by the TGF-beta superfamily. *Science* **296** 1646–1647. (<https://doi.org/10.1126/science.1071809>)
- Baenziger JU & Green ED 1988 Pituitary glycoprotein hormone oligosaccharides: structure, synthesis and function of the asparagine-linked oligosaccharides on lutropin, follitropin and thyrotropin. *Biochimica et Biophysica Acta* **947** 287–306. ([https://doi.org/10.1016/0304-4157\(88\)90012-3](https://doi.org/10.1016/0304-4157(88)90012-3))
- Bailey JS, Rave-Harel N, McGillivray SM, Coss D & Mellon PL 2004 Activin regulation of the follicle-stimulating hormone beta-subunit gene involves Smads and the TALE homeodomain proteins Pbx1 and Prep1. *Molecular Endocrinology* **18** 1158–1170. (<https://doi.org/10.1210/me.2003-0442>)
- Baratta M, West LA, Turzillo AM & Nett TM 2001 Activin modulates differential effects of estradiol on synthesis and secretion of follicle-stimulating hormone in ovine pituitary cells. *Biology of Reproduction* **64** 714–719. (<https://doi.org/10.1095/biolreprod64.2.714>)
- Barrios-De-Tomasi J, Timossi C, Merchant H, Quintanar A, Avalos JM, Andersen CY & Ulloa-Aguirre A 2002 Assessment of the *in vitro* and *in vivo* biological activities of the human follicle-stimulating isohormones. *Molecular and Cellular Endocrinology* **186** 189–198. ([https://doi.org/10.1016/S0303-7207\(01\)00657-8](https://doi.org/10.1016/S0303-7207(01)00657-8))
- Baumgarten SC, Convissar SM, Zamah AM, Fierro MA, Winston NJ, Scoccia B & Stocco C 2015 FSH regulates IGF-2 expression in human granulosa cells in an AKT-dependent manner. *Journal of Clinical Endocrinology and Metabolism* **100** E1046–E1055. (<https://doi.org/10.1210/jc.2015-1504>)
- Bernard DJ 2004 Both SMAD2 and SMAD3 mediate activin-stimulated expression of the follicle-stimulating hormone beta subunit in mouse gonadotrope cells. *Molecular Endocrinology* **18** 606–623. (<https://doi.org/10.1210/me.2003-0264>)
- Bernard DJ & Tran S 2013 Mechanisms of activin-stimulated FSH synthesis: the story of a pig and a FOX. *Biology of Reproduction* **88** 78. (<https://doi.org/10.1095/biolreprod.113.107797>)
- Binder AK, Grammer JC, Herndon MK, Stanton JD & Nilson JH 2012 GnRH regulation of Jun and Atf3 requires calcium, calcineurin, and NFAT. *Molecular Endocrinology* **26** 873–886. (<https://doi.org/10.1210/me.2012-1045>)
- Boerboom D, Kumar V, Boyer A, Wang Y, Lambrot R, Zhou X, Rico C, Boehm U, Paquet M, Celeste C, *et al.* 2015 β -Catenin stabilization in gonadotropes impairs FSH synthesis in male mice *in vivo*. *Endocrinology* **156** 323–333. (<https://doi.org/10.1210/en.2014-1296>)
- Bohnsack BL, Szabo M, Kilen SM, Tam DH & Schwartz NB 2000 Follistatin suppresses steroid-enhanced follicle-stimulating hormone release *in vitro* in rats. *Biology of Reproduction* **62** 636–641. (<https://doi.org/10.1095/biolreprod62.3.636>)
- Bokar JA, Keri RA, Farmerie TA, Fenstermaker RA, Andersen B, Hamernik DL, Yun J, Wagner T & Nilson JH 1989 Expression of the glycoprotein hormone alpha-subunit gene in the placenta requires a functional cyclic AMP response element, whereas a different cis-acting element mediates pituitary-specific expression. *Molecular and Cellular Biology* **9** 5113–5122. (<https://doi.org/10.1128/MCB.9.11.5113>)
- Bonfil D, Chuderland D, Kraus S, Shahbazian D, Friedberg I, Seger R & Naor Z 2004 Extracellular signal-regulated kinase, Jun N-terminal kinase, p38, and c-Src are involved in gonadotropin-releasing hormone-stimulated activity of the glycoprotein hormone follicle-stimulating hormone beta-subunit promoter. *Endocrinology* **145** 2228–2244. (<https://doi.org/10.1210/en.2003-1418>)
- Bouabe H & Okkenhaug K 2013 Gene targeting in mice: a review. *Methods in Molecular Biology* **1064** 315–336. (https://doi.org/10.1007/978-1-62703-601-6_23)
- Bousfield GR & Dias JA 2011 Synthesis and secretion of gonadotropins including structure-function correlates. *Reviews in Endocrine and Metabolic Disorders* **12** 289–302. (<https://doi.org/10.1007/s11154-011-9191-3>)
- Bousfield GR, Jia L & Ward DN 2006 Gonadotropins: chemistry and biosynthesis. In *Knobil's Physiology of Reproduction*, 3rd ed., pp 1581–1634. Ed. JD Neill. Amsterdam: Academic Press.
- Bousfield GR, Butnev VY, Walton WJ, Nguyen VT, Huneidi J, Singh V, Kolli VS, Harvey DJ & Rance NE 2007 All-or-none N-glycosylation in primate follicle-stimulating hormone beta-subunits. *Molecular and*

- Cellular Endocrinology* **260–262** 40–48. (<https://doi.org/10.1016/j.mce.2006.02.017>)
- Bousfield GR, Butnev VY, Butnev VY, Hiromasa Y, Harvey DJ & May JV 2014 Hypo-glycosylated human follicle-stimulating hormone (hFSH(21/18)) is much more active *in vitro* than fully-glycosylated hFSH (hFSH(24)). *Molecular and Cellular Endocrinology* **382** 989–997. (<https://doi.org/10.1016/j.mce.2013.11.008>)
- Burger LL, Haisenleder DJ, Dalkin AC & Marshall JC 2004 Regulation of gonadotropin subunit gene transcription. *Journal of Molecular Endocrinology* **33** 559–584. (<https://doi.org/10.1677/jme.1.01600>)
- Burger LL, Haisenleder DJ, Wotton GM, Aylor KW, Dalkin AC & Marshall JC 2007 The regulation of FSHbeta transcription by gonadal steroids: testosterone and estradiol modulation of the activin intracellular signaling pathway. *American Journal of Physiology: Endocrinology and Metabolism* **293** E277–E285. (<https://doi.org/10.1152/ajpendo.00447.2006>)
- Burrin JM & Jameson JL 1989 Regulation of transfected glycoprotein hormone alpha-gene expression in primary pituitary cell cultures. *Molecular Endocrinology* **3** 1643–1651. (<https://doi.org/10.1210/mend-3-10-1643>)
- Butler ST, Pelton SH, Knight PG & Butler WR 2008 Follicle-stimulating hormone isoforms and plasma concentrations of estradiol and inhibin A in dairy cows with ovulatory and non-ovulatory follicles during the first postpartum follicle wave. *Domestic Animal Endocrinology* **35** 112–119. (<https://doi.org/10.1016/j.domaniend.2008.03.002>)
- Butnev VY, Gotschall RR, Baker VL, Moore WT & Bousfield GR 1996 Negative influence of O-linked oligosaccharides of high molecular weight equine chorionic gonadotropin on its luteinizing hormone and follicle-stimulating hormone receptor-binding activities. *Endocrinology* **137** 2530–2542. (<https://doi.org/10.1210/endo.137.6.8641207>)
- Butnev VY, Butnev VY, May JV, Shuai B, Tran P, White WK, Brown A, Smalter Hall A, Harvey DJ, Bousfield GR, *et al.* 2015 Production, purification, and characterization of recombinant hFSH glycoforms for functional studies. *Molecular and Cellular Endocrinology* **405** 42–51. (<https://doi.org/10.1016/j.mce.2015.01.026>)
- Calvo FO, Keutmann HT, Bergert ER & Ryan RJ 1986 Deglycosylated human follitropin: characterization and effects on adenosine cyclic 3',5'-phosphate production in porcine granulosa cells. *Biochemistry* **25** 3938–3943. (<https://doi.org/10.1021/bi00361a030>)
- Cannon JG, Kraj B & Sloan G 2011 Follicle-stimulating hormone promotes RANK expression on human monocytes. *Cytokine* **53** 141–144. (<https://doi.org/10.1016/j.cyto.2010.11.011>)
- Choi SG, Ruf-Zamojski F, Pincas H, Roysam B & Sealfon SC 2011 Characterization of a MAPK scaffolding protein logic gate in gonadotropes. *Molecular Endocrinology* **25** 1027–1039. (<https://doi.org/10.1210/me.2010-0387>)
- Ciccone NA, Lacza CT, Hou MY, Gregory SJ, Kam KY, Xu S & Kaiser UB 2008 A composite element that binds basic helix loop helix and basic leucine zipper transcription factors is important for gonadotropin-releasing hormone regulation of the follicle-stimulating hormone beta gene. *Molecular Endocrinology* **22** 1908–1923. (<https://doi.org/10.1210/me.2007-0455>)
- Ciccone NA, Xu S, Lacza CT, Carroll RS & Kaiser UB 2010 Frequency-dependent regulation of follicle-stimulating hormone beta by pulsatile gonadotropin-releasing hormone is mediated by functional antagonism of bZIP transcription factors. *Molecular and Cellular Biology* **30** 1028–1040. (<https://doi.org/10.1128/MCB.00848-09>)
- Clarke HJ 2018 Regulation of germ cell development by intercellular signaling in the mammalian ovarian follicle. *Wiley Interdisciplinary Reviews: Developmental Biology* **7** e294. (<https://doi.org/10.1002/wdev.294>)
- Combarnous Y 1992 Molecular basis of the specificity of binding of glycoprotein hormones to their receptors. *Endocrine Reviews* **13** 670–691. (<https://doi.org/10.1210/edrv-13-4-670>)
- Combelles CM, Carabatsos MJ, Kumar TR, Matzuk MM & Albertini DF 2004 Hormonal control of somatic cell oocyte interactions during ovarian follicle development. *Molecular Reproduction and Development* **69** 347–355. (<https://doi.org/10.1002/mrd.20128>)
- Corrigan AZ, Bilezikjian LM, Carroll RS, Bald LN, Schmelzer CH, Fendly BM, Mason AJ, Chin WW, Schwall RH & Vale W 1991 Evidence for an autocrine role of activin B within rat anterior pituitary cultures. *Endocrinology* **128** 1682–1684. (<https://doi.org/10.1210/endo-128-3-1682>)
- Coss D, Jacobs SB, Bender CE & Mellon PL 2004 A novel AP-1 site is critical for maximal induction of the follicle-stimulating hormone beta gene by gonadotropin-releasing hormone. *Journal of Biological Chemistry* **279** 152–162. (<https://doi.org/10.1074/jbc.M304697200>)
- Coss D, Hand CM, Yaphockun KK, Ely HA & Mellon PL 2007 p38 mitogen-activated protein kinase is critical for synergistic induction of the FSH(beta) gene by gonadotropin-releasing hormone and activin through augmentation of c-Fos induction and Smad phosphorylation. *Molecular Endocrinology* **21** 3071–3086. (<https://doi.org/10.1210/me.2007-0247>)
- Cotton J, Salvador LM, Maizels ET, Reierstad S, Park Y, Carr DW, Davare MA, Hell JW, Palmer SS, Dent P, *et al.* 2003 Follicle-stimulating hormone activates extracellular signal-regulated kinase but not extracellular signal-regulated kinase through a 100-kDa phosphotyrosine phosphatase. *Journal of Biological Chemistry* **278** 7167–7179. (<https://doi.org/10.1074/jbc.M203901200>)
- Couse JF, Yates MM, Walker VR & Korach KS 2003 Characterization of the hypothalamic-pituitary-gonadal axis in estrogen receptor (ER) Null mice reveals hypergonadism and endocrine sex reversal in females lacking ERalpha but not ERbeta. *Molecular Endocrinology* **17** 1039–1053. (<https://doi.org/10.1210/me.2002-0398>)
- Crepieux P, Marion S, Martinat N, Fafeur Y, Vern YL, Kerboeuf D, Guillou F & Reiter E 2001 The ERK-dependent signalling is stage-specifically modulated by FSH, during primary Sertoli cell maturation. *Oncogene* **20** 4696–4709. (<https://doi.org/10.1038/sj.onc.1204632>)
- Cui Q, Yu Z, Purisima EO & Wang E 2006 Principles of microRNA regulation of a human cellular signaling network. *Molecular Systems Biology* **2** 46. (<https://doi.org/10.1038/msb4100089>)
- Dalkin AC, Haisenleder DJ, Ortolano GA, Ellis TR & Marshall JC 1989 The frequency of gonadotropin-releasing-hormone stimulation differentially regulates gonadotropin subunit messenger ribonucleic acid expression. *Endocrinology* **125** 917–924. (<https://doi.org/10.1210/endo-125-2-917>)
- Dalkin AC, Knight CD, Shupnik MA, Haisenleder DJ, Aloï J, Kirk SE, Yasin M & Marshall JC 1993 Ovariectomy and inhibin immunoneutralization acutely increase follicle-stimulating hormone-beta messenger ribonucleic acid concentrations: evidence for a nontranscriptional mechanism. *Endocrinology* **132** 1297–1304. (<https://doi.org/10.1210/endo.132.3.7679976>)
- Dalkin AC, Burger LL, Aylor KW, Haisenleder DJ, Workman LJ, Cho S & Marshall JC 2001 Regulation of gonadotropin subunit gene transcription by gonadotropin-releasing hormone: measurement of primary transcript ribonucleic acids by quantitative reverse transcription-polymerase chain reaction assays. *Endocrinology* **142** 139–146. (<https://doi.org/10.1210/endo.142.1.7881>)
- Dattatreyaamurti B, Figs LW & Reichert LE Jr 1987 Physical and functional association of follitropin receptors with cholera toxin-sensitive guanine nucleotide-binding protein. *Journal of Biological Chemistry* **262** 11737–11745.
- Daude N, Lestage J, Reichardt JK & Petry KG 1996 Expression of galactose-1-phosphate uridylyltransferase in the anterior pituitary of rat during the estrous cycle. *Neuroendocrinology* **64** 42–48. (<https://doi.org/10.1159/000127096>)
- Deng CX 2014 Conditional knockout mouse models of cancer. *Cold Spring Harbor Protocols* **2014** 1217–1233.

- Dias JA, Mahale SD, Nechamen CA, Davydenko O, Thomas RM & Ulloa-Aguirre A 2010 Emerging roles for the FSH receptor adapter protein APPL1 and overlap of a putative 14-3-3tau interaction domain with a canonical G-protein interaction site. *Molecular and Cellular Endocrinology* **329** 17–25. (<https://doi.org/10.1016/j.mce.2010.05.009>)
- Dierich A, Sairam MR, Monaco L, Fimia GM, Gansmuller A, LeMeur M & Sassone-Corsi P 1998 Impairing follicle-stimulating hormone (FSH) signaling in vivo: targeted disruption of the FSH receptor leads to aberrant gametogenesis and hormonal imbalance. *PNAS* **95** 13612–13617. (<https://doi.org/10.1073/pnas.95.23.13612>)
- Donaubauer EM, Law NC & Hunzicker-Dunn ME 2016 Follicle-stimulating hormone (FSH)-dependent regulation of extracellular regulated kinase (ERK) phosphorylation by the mitogen-activated protein (MAP) kinase phosphatase MKP3. *Journal of Biological Chemistry* **291** 19701–19712. (<https://doi.org/10.1074/jbc.M116.733972>)
- Dubois SL, Wolfe A, Radovick S, Boehm U & Levine JE 2016 Estradiol restrains prepubertal gonadotropin secretion in female mice via activation of ERalpha in kisspeptin neurons. *Endocrinology* **157** 1546–1554. (<https://doi.org/10.1210/en.2015-1923>)
- El-Hayek S & Clarke HJ 2015 Follicle-stimulating hormone increases gap junctional communication between somatic and germ-line follicular compartments during murine oogenesis. *Biology of Reproduction* **93** 47. (<https://doi.org/10.1095/biolreprod.115.129569>)
- El-Hayek S, Demeestere I & Clarke HJ 2014 Follicle-stimulating hormone regulates expression and activity of epidermal growth factor receptor in the murine ovarian follicle. *PNAS* **111** 16778–16783. (<https://doi.org/10.1073/pnas.1414648111>)
- Escamilla-Hernandez R, Little-Ihrig L & Zeleznik AJ 2008 Inhibition of rat granulosa cell differentiation by overexpression of Galphaq. *Endocrine* **33** 21–31. (<https://doi.org/10.1007/s12020-008-9064-z>)
- Farh KK, Grimson A, Jan C, Lewis BP, Johnston WK, Lim LP, Burge CB & Bartel DP 2005 The widespread impact of mammalian MicroRNAs on mRNA repression and evolution. *Science* **310** 1817–1821. (<https://doi.org/10.1126/science.1121158>)
- Faure MO, Nicol L, Fabre S, Fontaine J, Mohoric N, McNeilly A & Taragnat C 2005 BMP-4 inhibits follicle-stimulating hormone secretion in ewe pituitary. *Journal of Endocrinology* **186** 109–121. (<https://doi.org/10.1677/joe.1.05988>)
- Fortin J, Boehm U, Deng CX, Treier M & Bernard DJ 2014 Follicle-stimulating hormone synthesis and fertility depend on SMAD4 and FOXL2. *FASEB Journal* **28** 3396–3410. (<https://doi.org/10.1096/fj.14-249532>)
- Fowkes RC & Burrin JM 2003 Steroidogenic factor-1 enhances basal and forskolin-stimulated transcription of the human glycoprotein hormone alpha-subunit gene in GH3 cells. *Journal of Endocrinology* **179** R1–R6. (<https://doi.org/10.1677/joe.0.179R001>)
- Fowkes RC, King P & Burrin JM 2002 Regulation of human glycoprotein hormone alpha-subunit gene transcription in LbetaT2 gonadotropes by protein kinase C and extracellular signal-regulated kinase 1/2. *Biology of Reproduction* **67** 725–734. (<https://doi.org/10.1095/biolreprod67.3.725>)
- Fox N & Solter D 1988 Expression and regulation of the pituitary- and placenta-specific human glycoprotein hormone alpha-subunit gene is restricted to the pituitary in transgenic mice. *Molecular and Cellular Biology* **8** 5470–5476. (<https://doi.org/10.1128/MCB.8.12.5470>)
- Gloaguen P, Crepieux P, Heitzler D, Poupon A & Reiter E 2011 Mapping the follicle-stimulating hormone-induced signaling networks. *Frontiers in Endocrinology* **2** 45. (<https://doi.org/10.3389/fendo.2011.00045>)
- Gonzalez-Robayna IJ, Falender AE, Ochsner S, Firestone GL & Richards JS 2000 Follicle-Stimulating hormone (FSH) stimulates phosphorylation and activation of protein kinase B (PKB/Akt) and serum and glucocorticoid-induced kinase (Sgk): evidence for a kinase-independent signaling by FSH in granulosa cells. *Molecular Endocrinology* **14** 1283–1300. (<https://doi.org/10.1210/mend.14.8.0500>)
- Gordon A, Aguilar R, Garrido-Gracia JC, Guil-Luna S, Sanchez Cespedes R, Millan Y, Watanabe G, Taya K, Martin de Las Mulas J & Sanchez-Criado JE 2010 Immunoneutralization of inhibin in cycling rats increases follicle-stimulating hormone secretion, stimulates the ovary and attenuates progesterone receptor-dependent preovulatory luteinizing hormone secretion. *Neuroendocrinology* **91** 291–301. (<https://doi.org/10.1159/000299791>)
- Gregory SJ & Kaiser UB 2004 Regulation of gonadotropins by inhibin and activin. *Seminars in Reproductive Medicine* **22** 253–267. (<https://doi.org/10.1055/s-2004-831901>)
- Gregory SJ, Lacza CT, Detz AA, Xu S, Petrillo LA & Kaiser UB 2005 Synergy between activin A and gonadotropin-releasing hormone in transcriptional activation of the rat follicle-stimulating hormone-beta gene. *Molecular Endocrinology* **19** 237–254. (<https://doi.org/10.1210/me.2003-0473>)
- Guo Q, Kumar TR, Woodruff T, Hadsell LA, DeMayo FJ & Matzuk MM 1998 Overexpression of mouse follistatin causes reproductive defects in transgenic mice. *Molecular Endocrinology* **12** 96–106. (<https://doi.org/10.1210/mend.12.1.0053>)
- Haisenleder DJ, Katt JA, Ortolano GA, el-Gewely MR, Duncan JA, Dee C & Marshall JC 1988 Influence of gonadotropin-releasing hormone pulse amplitude, frequency, and treatment duration on the regulation of luteinizing hormone (LH) subunit messenger ribonucleic acids and LH secretion. *Molecular Endocrinology* **2** 338–343. (<https://doi.org/10.1210/mend-2-4-338>)
- Haisenleder DJ, Ferris HA & Shupnik MA 2003 The calcium component of gonadotropin-releasing hormone-stimulated luteinizing hormone subunit gene transcription is mediated by calcium/calmodulin-dependent protein kinase type II. *Endocrinology* **144** 2409–2416. (<https://doi.org/10.1210/en.2002-0013>)
- Haj M, Wijeweera A, Rudnizky S, Taunton J, Pnueli L & Melamed P 2017 Mitogen and stress-activated protein kinase 1 is required for gonadotropin-releasing hormone-mediated activation of gonadotropin alpha subunit expression. *Journal of Biological Chemistry* **292** 20720–20731. (<https://doi.org/10.1074/jbc.M117.797845>)
- Halvorson LM, Weiss J, Bauer-Dantoin AC & Jameson JL 1994 Dynamic regulation of pituitary follistatin messenger ribonucleic acids during the rat estrous cycle. *Endocrinology* **134** 1247–1253. (<https://doi.org/10.1210/endo.134.3.8119165>)
- Haywood M, Spaliviero J, Jimenez M, King NJ, Handelsman DJ & Allan CM 2003 Sertoli and germ cell development in hypogonadal (hpg) mice expressing transgenic follicle-stimulating hormone alone or in combination with testosterone. *Endocrinology* **144** 509–517. (<https://doi.org/10.1210/en.2002-220710>)
- He B, Mi Y & Zhang C 2013 Gonadotropins regulate ovarian germ cell mitosis/meiosis decision in the embryonic chicken. *Molecular and Cellular Endocrinology* **370** 32–41. (<https://doi.org/10.1016/j.mce.2013.02.010>)
- Herath CB, Yamashita M, Watanabe G, Jin W, Tangtrongsup S, Kojima A, Groome NP, Suzuki AK & Taya K 2001 Regulation of follicle-stimulating hormone secretion by estradiol and dimeric inhibins in the infantile female rat. *Biology of Reproduction* **65** 1623–1633. (<https://doi.org/10.1095/biolreprod65.6.1623>)
- Herndon MK, Law NC, Donaubauer EM, Kyriass B & Hunzicker-Dunn M 2016 Forkhead box O member FOXO1 regulates the majority of follicle-stimulating hormone responsive genes in ovarian granulosa cells. *Molecular and Cellular Endocrinology* **434** 116–126. (<https://doi.org/10.1016/j.mce.2016.06.020>)
- Hiipakka RA & Liao S 1998 Molecular mechanism of androgen action. *Trends in Endocrinology and Metabolism* **9** 317–324. ([https://doi.org/10.1016/S1043-2760\(98\)00081-2](https://doi.org/10.1016/S1043-2760(98)00081-2))
- Howles CM 2000 Role of LH and FSH in ovarian function. *Molecular and Cellular Endocrinology* **161** 25–30. ([https://doi.org/10.1016/S0303-7207\(99\)00219-1](https://doi.org/10.1016/S0303-7207(99)00219-1))
- Huhtaniemi IT & Themmen AP 2005 Mutations in human gonadotropin and gonadotropin-receptor genes. *Endocrine* **26** 207–217. (<https://doi.org/10.1385/ENDO:26:3:207>)

- Huhtaniemi I, Ahtiainen P, Pakarainen T, Rulli SB, Zhang FP & Poutanen M 2006 Genetically modified mouse models in studies of luteinising hormone action. *Molecular and Cellular Endocrinology* **252** 126–135. (<https://doi.org/10.1016/j.mce.2006.03.026>)
- Ide H, Terado Y, Sakamaki K, Inoue M, Nakajima A, Lu Y, Hisasue S, Yamaguchi R, Muto S & Horie S 2013 Serum level of follicle-stimulating hormone is associated with extraprostatic extension of prostate cancer. *Prostate International* **1** 109–112. (<https://doi.org/10.12954/PI.13019>)
- Ioffe E & Stanley P 1994 Mice lacking N-acetylglucosaminyltransferase I activity die at mid-gestation, revealing an essential role for complex or hybrid N-linked carbohydrates. *PNAS* **91** 728–732. (<https://doi.org/10.1073/pnas.91.2.728>)
- Jiang C, Hou X, Wang C, May JV, Butnev VY, Bousfield GR & Davis JS 2015 Hypoglycosylated hFSH has greater bioactivity than fully glycosylated recombinant hFSH in human granulosa cells. *Journal of Clinical Endocrinology and Metabolism* **100** E852–E860. (<https://doi.org/10.1210/jc.2015-1317>)
- Johnson RS, Spiegelman BM & Papaioannou V 1992 Pleiotropic effects of a null mutation in the c-fos proto-oncogene. *Cell* **71** 577–586. ([https://doi.org/10.1016/0092-8674\(92\)90592-Z](https://doi.org/10.1016/0092-8674(92)90592-Z))
- Jorgez CJ, Klyzik M, Jamin SP, Behringer RR & Matzuk MM 2004 Granulosa cell-specific inactivation of follistatin causes female fertility defects. *Molecular Endocrinology* **18** 953–967. (<https://doi.org/10.1210/me.2003-0301>)
- Justice NJ, Blount AL, Pelosi E, Schlessinger D, Vale W & Bilezikjian LM 2011 Impaired FSHbeta expression in the pituitaries of Foxl2 mutant animals. *Molecular Endocrinology* **25** 1404–1415. (<https://doi.org/10.1210/me.2011-0093>)
- Kaiser UB, Conn PM & Chin WW 1997 Studies of gonadotropin-releasing hormone (GnRH) action using GnRH receptor-expressing pituitary cell lines. *Endocrine Reviews* **18** 46–70. (<https://doi.org/10.1210/edrv.18.1.0289>)
- Kakar SS, Winters SJ, Zacharias W, Miller DM & Flynn S 2003 Identification of distinct gene expression profiles associated with treatment of LbetaT2 cells with gonadotropin-releasing hormone agonist using microarray analysis. *Gene* **308** 67–77. ([https://doi.org/10.1016/S0378-1119\(03\)00446-3](https://doi.org/10.1016/S0378-1119(03)00446-3))
- Kelleher DJ, Karaoglu D, Mandon EC & Gilmore R 2003 Oligosaccharyltransferase isoforms that contain different catalytic STT3 subunits have distinct enzymatic properties. *Molecular Cell* **12** 101–111. ([https://doi.org/10.1016/S1097-2765\(03\)00243-0](https://doi.org/10.1016/S1097-2765(03)00243-0))
- Kendall SK, Samuelson LC, Saunders TL, Wood RI & Camper SA 1995 Targeted disruption of the pituitary glycoprotein hormone alpha-subunit produces hypogonadal and hypothyroid mice. *Genes and Development* **9** 2007–2019. (<https://doi.org/10.1101/gad.9.16.2007>)
- Kiezun M, Smolinska N, Maleszka A, Dobrzyn K, Szeszko K & Kaminski T 2014 Adiponectin expression in the porcine pituitary during the estrous cycle and its effect on LH and FSH secretion. *American Journal of Physiology: Endocrinology and Metabolism* **307** E1038–E1046. (<https://doi.org/10.1152/ajpendo.00299.2014>)
- Kilen SM, Szabo M, Strasser GA, McAndrews JM, Ringstrom SJ & Schwartz NB 1996 Corticosterone selectively increases follicle-stimulating hormone beta-subunit messenger ribonucleic acid in primary anterior pituitary cell culture without affecting its half-life. *Endocrinology* **137** 3802–3807. (<https://doi.org/10.1210/endo.137.9.8756550>)
- Kim T & Lawson MA 2015 GnRH regulates gonadotropin gene expression through NADPH/dual oxidase-derived reactive oxygen species. *Endocrinology* **156** 2185–2199. (<https://doi.org/10.1210/en.2014-1709>)
- Kishi H, Krishnamurthy H, Galet C, Bhaskaran RS & Ascoli M 2002 Identification of a short linear sequence present in the C-terminal tail of the rat follitropin receptor that modulates arrestin-3 binding in a phosphorylation-independent fashion. *Journal of Biological Chemistry* **277** 21939–21946. (<https://doi.org/10.1074/jbc.M110894200>)
- Knox KL & Schwartz NB 1992 RU486 blocks the secondary surge of follicle-stimulating hormone in the rat without blocking the drop in serum inhibin. *Biology of Reproduction* **46** 220–225. (<https://doi.org/10.1095/biolreprod46.2.220>)
- Krishnamurthy H, Galet C & Ascoli M 2003 The association of arrestin-3 with the follitropin receptor depends on receptor activation and phosphorylation. *Molecular and Cellular Endocrinology* **204** 127–140. ([https://doi.org/10.1016/S0303-7207\(03\)00088-1](https://doi.org/10.1016/S0303-7207(03)00088-1))
- Kumar TR 2016 Mouse models for the study of synthesis, secretion, and action of pituitary gonadotropins. *Progress in Molecular Biology and Translational Science* **143** 49–84.
- Kumar TR 2018 Extragonadal actions of FSH: a critical need for novel genetic models. *Endocrinology* **159** 2–8. (<https://doi.org/10.1210/en.2017-03118>)
- Kumar TR & Low MJ 1993 Gonadal steroid hormone regulation of human and mouse follicle stimulating hormone beta-subunit gene expression in vivo. *Molecular Endocrinology* **7** 898–906. (<https://doi.org/10.1210/mend.7.7.8413314>)
- Kumar TR & Low MJ 1995 Hormonal regulation of human follicle-stimulating hormone-beta subunit gene expression: GnRH stimulation and GnRH-independent androgen inhibition. *Neuroendocrinology* **61** 628–637. (<https://doi.org/10.1159/000126889>)
- Kumar TR, Fairchild-Huntress V & Low MJ 1992 Gonadotrope-specific expression of the human follicle-stimulating hormone beta-subunit gene in pituitaries of transgenic mice. *Molecular Endocrinology* **6** 81–90. (<https://doi.org/10.1210/mend.6.1.1738375>)
- Kumar TR, Wang Y, Lu N & Matzuk MM 1997 Follicle stimulating hormone is required for ovarian follicle maturation but not male fertility. *Nature Genetics* **15** 201–204. (<https://doi.org/10.1038/ng0297-201>)
- Kumar TR, Low MJ & Matzuk MM 1998 Genetic rescue of follicle-stimulating hormone beta-deficient mice. *Endocrinology* **139** 3289–3295. (<https://doi.org/10.1210/endo.139.7.6111>)
- Kumar TR, Palapattu G, Wang P, Woodruff TK, Boime I, Byrne MC & Matzuk MM 1999 Transgenic models to study gonadotropin function: the role of follicle-stimulating hormone in gonadal growth and tumorigenesis. *Molecular Endocrinology* **13** 851–865. (<https://doi.org/10.1210/mend.13.6.0297>)
- Kumar TR, Schuff KG, Nusser KD & Low MJ 2006 Gonadotroph-specific expression of the human follicle stimulating hormone beta gene in transgenic mice. *Molecular and Cellular Endocrinology* **247** 103–115. (<https://doi.org/10.1016/j.mce.2005.12.006>)
- Kumar TR, Larson M, Wang H, McDermott J & Bronshteyn I 2009 Transgenic mouse technology: principles and methods. *Methods in Molecular Biology* **590** 335–362. (https://doi.org/10.1007/978-1-60327-378-7_22)
- Kutteyil SS, Pathak BR & Mahale SD 2017 Transcriptional regulation of follicle-stimulating hormone beta-subunit in marmoset by an alternate distal promoter. *General and Comparative Endocrinology* **246** 331–336. (<https://doi.org/10.1016/j.ygcen.2017.01.009>)
- Lamba P, Khivansara V, D'Alessio AC, Santos MM & Bernard DJ 2008 Paired-like homeodomain transcription factors 1 and 2 regulate follicle-stimulating hormone beta-subunit transcription through a conserved cis-element. *Endocrinology* **149** 3095–3108. (<https://doi.org/10.1210/en.2007-0425>)
- Lane EA, Padmanabhan V, Roche JF & Crowe MA 2005 Alterations in the ability of the bovine pituitary gland to secrete gonadotropins in vitro during the first follicle-stimulating hormone increase of the estrous cycle and in response to exogenous steroids. *Domestic Animal Endocrinology* **28** 190–201. (<https://doi.org/10.1016/j.domaniend.2004.09.001>)
- Lannes J, L'Hote D, Garrel G, Laverriere JN, Cohen-Tannoudji J & Querat B 2015 Rapid communication: a microRNA-132/212 pathway

- mediates GnRH activation of FSH expression. *Molecular Endocrinology* **29** 364–372. (<https://doi.org/10.1210/me.2014-1390>)
- Lannes J, L'Hôte D, Fernandez-Vega A, Garrel G, Laverrière JN, Joelle Cohen T & Quérat B 2016 A regulatory loop between miR-132 and miR-125b involved in gonadotrope cells desensitization to GnRH. *Scientific Reports* **6** 31563. (<https://doi.org/10.1038/srep31563>)
- Layman LC, Lee EJ, Peak DB, Namnoum AB, Vu KV, van Ling BL, Gray MR, McDonough PG, Reindollar RH & Jameson JL 1997 Delayed puberty and hypogonadism caused by mutations in the follicle-stimulating hormone beta-subunit gene. *New England Journal of Medicine* **337** 607–611. (<https://doi.org/10.1056/NEJM199708283370905>)
- Leal AM, Blount AL, Donaldson CJ, Bilezikjian LM & Vale WW 2003 Regulation of follicle-stimulating hormone secretion by the interactions of activin-A, dexamethasone and testosterone in anterior pituitary cell cultures of male rats. *Neuroendocrinology* **77** 298–304. (<https://doi.org/10.1159/000070896>)
- Lee KB, Khivansara V, Santos MM, Lamba P, Yuen T, Sealfon SC & Bernard DJ 2007 Bone morphogenetic protein 2 and activin A synergistically stimulate follicle-stimulating hormone beta subunit transcription. *Journal of Molecular Endocrinology* **38** 315–330. (<https://doi.org/10.1677/jme.1.02196>)
- Lefkowitz RJ & Shenoy SK 2005 Transduction of receptor signals by beta-arrestins. *Science* **308** 512–517. (<https://doi.org/10.1126/science.1109237>)
- Levine JE, Chappell PE, Schneider JS, Sleiter NC & Szabo M 2001 Progesterone receptors as neuroendocrine integrators. *Frontiers in Neuroendocrinology* **22** 69–106. (<https://doi.org/10.1006/frne.2001.0210>)
- Li Y, Schang G, Boehm U, Deng CX, Graff J & Bernard DJ 2017 SMAD3 regulates follicle-stimulating hormone synthesis by pituitary gonadotrope cells in vivo. *Journal of Biological Chemistry* **292** 2301–2314. (<https://doi.org/10.1074/jbc.M116.759167>)
- Lin YF, Tseng MJ, Hsu HL, Wu YW, Lee YH & Tsai YH 2006 A novel follicle-stimulating hormone-induced G alpha h/phospholipase C-delta1 signaling pathway mediating rat sertoli cell Ca2+-influx. *Molecular Endocrinology* **20** 2514–2527. (<https://doi.org/10.1210/me.2005-0347>)
- Lin X, Rice KL, Buzzai M, Hexner E, Costa FF, Kilpivaara O, Mullally A, Soares MB, Ebert BL, Levine R, et al. 2013 miR-433 is aberrantly expressed in myeloproliferative neoplasms and suppresses hematopoietic cell growth and differentiation. *Leukemia* **27** 344–352. (<https://doi.org/10.1038/leu.2012.224>)
- Ling N, Ying SY, Ueno N, Shimasaki S, Esch F, Hotta M & Guillemin R 1986 Pituitary FSH is released by a heterodimer of the beta-subunits from the two forms of inhibin. *Nature* **321** 779–782. (<https://doi.org/10.1038/321779a0>)
- Liu F, Austin DA, Mellon PL, Olefsky JM & Webster NJ 2002 GnRH activates ERK1/2 leading to the induction of c-fos and LHbeta protein expression in LbetaT2 cells. *Molecular Endocrinology* **16** 419–434. (<https://doi.org/10.1210/mend.16.2.0769>)
- Liu F, Ruiz MS, Austin DA & Webster NJ 2005 Constitutively active Gq impairs gonadotropin-releasing hormone-induced intracellular signaling and luteinizing hormone secretion in LbetaT2 cells. *Molecular Endocrinology* **19** 2074–2085. (<https://doi.org/10.1210/me.2004-0145>)
- Liu S, Cheng Y, Fan M, Chen D & Bian Z 2010 FSH aggravates periodontitis-related bone loss in ovariectomized rats. *Journal of Dental Research* **89** 366–371. (<https://doi.org/10.1177/0022034509358822>)
- Liu P, Ji Y, Yuen T, Rendina-Ruedy E, DeMambro VE, Dhawan S, Abu-Amer W, Izadmehr S, Zhou B, Shin AC, et al. 2017 Blocking FSH induces thermogenic adipose tissue and reduces body fat. *Nature* **546** 107–112. (<https://doi.org/10.1038/nature22342>)
- Loraine JA & Schmidt-Elmendorff HW 1963 Human gonadotrophins. *Modern Trends in Human Reproductive Physiology* **15** 18–43.
- Loreti N, Fresno C, Barrera D, Andreone L, Albarran SL, Fernandez EA, Larrea F & Campo S 2013 The glycan structure in recombinant human FSH affects endocrine activity and global gene expression in human granulosa cells. *Molecular and Cellular Endocrinology* **366** 68–80. (<https://doi.org/10.1016/j.mce.2012.11.021>)
- Ma X, Dong Y, Matzuk MM & Kumar TR 2004 Targeted disruption of luteinizing hormone beta-subunit leads to hypogonadism, defects in gonadal steroidogenesis, and infertility. *PNAS* **101** 17294–17299. (<https://doi.org/10.1073/pnas.0404743101>)
- Ma X, Reyna A, Mani SK, Matzuk MM & Kumar TR 2005 Impaired male sexual behavior in activin receptor type II knockout mice. *Biology of Reproduction* **73** 1182–1190. (<https://doi.org/10.1095/biolreprod.105.043794>)
- Manjunath P, Sairam MR & Sairam J 1982 Studies on pituitary follitropin. X. Biochemical, receptor binding and immunological properties of deglycosylated ovine hormone. *Molecular and Cellular Endocrinology* **28** 125–138. ([https://doi.org/10.1016/0303-7207\(82\)90026-0](https://doi.org/10.1016/0303-7207(82)90026-0))
- Marion S, Robert F, Crepieux P, Martinat N, Troispoux C, Guillou F & Reiter E 2002 G protein-coupled receptor kinases and beta arrestins are relocalized and attenuate cyclic 3',5'-adenosine monophosphate response to follicle-stimulating hormone in rat primary Sertoli cells. *Biology of Reproduction* **66** 70–76. (<https://doi.org/10.1095/biolreprod66.1.70>)
- Marion S, Kara E, Crepieux P, Piketty V, Martinat N, Guillou F & Reiter E 2006 G protein-coupled receptor kinase 2 and beta-arrestins are recruited to FSH receptor in stimulated rat primary Sertoli cells. *Journal of Endocrinology* **190** 341–350. (<https://doi.org/10.1677/joe.1.06857>)
- Martynska L, Wolinska-Witort E, Chmielowska M, Kalisz M, Baranowska B & Bik W 2014 Effect of orexin A on the release of GnRH-stimulated gonadotrophins from cultured pituitary cells of immature and mature female rats. *Neuropeptides* **48** 199–205. (<https://doi.org/10.1016/j.npep.2014.05.005>)
- Mason AJ, Hayflick JS, Zoeller RT, Young WS 3rd, Phillips HS, Nikolics K & Seeburg PH 1986 A deletion truncating the gonadotropin-releasing hormone gene is responsible for hypogonadism in the hpg mouse. *Science* **234** 1366–1371. (<https://doi.org/10.1126/science.3024317>)
- Massague J 1998 TGF-beta signal transduction. *Annual Review of Biochemistry* **67** 753–791. (<https://doi.org/10.1146/annurev.biochem.67.1.753>)
- Matthews CH, Borgato S, Beck-Peccoz P, Adams M, Tone Y, Gambino G, Casagrande S, Tedeschini G, Benedetti A & Chatterjee VK 1993 Primary amenorrhoea and infertility due to a mutation in the beta-subunit of follicle-stimulating hormone. *Nature Genetics* **5** 83–86. (<https://doi.org/10.1038/ng0993-83>)
- Matzuk MM, Finegold MJ, Su JG, Hsueh AJ & Bradley A 1992 Alpha-inhibin is a tumour-suppressor gene with gonadal specificity in mice. *Nature* **360** 313–319. (<https://doi.org/10.1038/360313a0>)
- Matzuk MM, Kumar TR & Bradley A 1995 Different phenotypes for mice deficient in either activins or activin receptor type II. *Nature* **374** 356–360. (<https://doi.org/10.1038/374356a0>)
- Maurer RA, Kim KE, Schoderbek WE, Roberson MS & Glenn DJ 1999 Regulation of glycoprotein hormone alpha-subunit gene expression. *Recent Progress in Hormone Research* **54** 455–484; discussion 485.
- McAndrews JM, Ringstrom SJ, Dahl KD & Schwartz NB 1994 Corticosterone in vivo increases pituitary follicle-stimulating hormone (FSH)-beta messenger ribonucleic acid content and serum FSH bioactivity selectively in female rats. *Endocrinology* **134** 158–163. (<https://doi.org/10.1210/endo.134.1.8275929>)
- McGillivray SM, Thackray VG, Coss D & Mellon PL 2007 Activin and glucocorticoids synergistically activate follicle-stimulating hormone beta-subunit gene expression in the immortalized LbetaT2 gonadotrope cell line. *Endocrinology* **148** 762–773. (<https://doi.org/10.1210/en.2006-0952>)

- McNeilly AS 1988 The control of FSH secretion. *Acta Endocrinologica Supplementum* **288** 31–40.
- McPhaul MJ & Young M 2001 Complexities of androgen action. *Journal of the American Academy of Dermatology* **45** S87–S94. (<https://doi.org/10.1067/mjd.2001.117429>)
- Meroni SB, Riera MF, Pellizzari EH & Cigorraga SB 2002 Regulation of rat Sertoli cell function by FSH: possible role of phosphatidylinositol 3-kinase/protein kinase B pathway. *Journal of Endocrinology* **174** 195–204. (<https://doi.org/10.1677/joe.0.1740195>)
- Mijidodj T, Kanasaki H, Sukhbaatar U, Oride A & Kyo S 2015 DS1, a delta subunit-containing GABA(A) receptor agonist, increases gonadotropin subunit gene expression in mouse pituitary gonadotrophs. *Biology of Reproduction* **92** 45. (<https://doi.org/10.1095/biolreprod.114.123893>)
- Moore LG, Ng Chie W, Hudson NL & McNatty KP 2000 Isoforms and half-life of FSH from sheep with different reproductive states. *Journal of Endocrinology* **165** 185–192. (<https://doi.org/10.1677/joe.0.1650185>)
- Moriyama R, Yamazaki T, Kato T & Kato Y 2016 Long-chain unsaturated fatty acids reduce the transcriptional activity of the rat follicle-stimulating hormone beta-subunit gene. *Journal of Reproduction and Development* **62** 195–199. (<https://doi.org/10.1262/jrd.2015-138>)
- Nakamura K, Krupnick JG, Benovic JL & Ascoli M 1998 Signaling and phosphorylation-impaired mutants of the rat follitropin receptor reveal an activation- and phosphorylation-independent but arrestin-dependent pathway for internalization. *Journal of Biological Chemistry* **273** 24346–24354. (<https://doi.org/10.1074/jbc.273.38.24346>)
- Naor Z 2009 Signaling by G-protein-coupled receptor (GPCR): studies on the GnRH receptor. *Frontiers in Neuroendocrinology* **30** 10–29. (<https://doi.org/10.1016/j.ymfe.2008.07.001>)
- Narayan P, Ulloa-Aguirre A & Dias JA 2018 Gonadotropin hormones and their receptors. In *Yen and Jaffe's Reproductive Endocrinology*, pp 25–57. Eds J Strauss, A Barbieri & A Gargiulo. Philadelphia: Elsevier.
- Nechamen CA, Thomas RM, Cohen BD, Acevedo G, Poulikakos PI, Testa JR & Dias JA 2004 Human follicle-stimulating hormone (FSH) receptor interacts with the adaptor protein APPL1 in HEK 293 cells: potential involvement of the PI3K pathway in FSH signaling. *Biology of Reproduction* **71** 629–636. (<https://doi.org/10.1095/biolreprod.103.025833>)
- Nicol L, Faure MO, McNeilly JR, Fontaine J, Taragnat C & McNeilly AS 2008 Bone morphogenetic protein-4 interacts with activin and GnRH to modulate gonadotrophin secretion in LbetaT2 gonadotrophs. *Journal of Endocrinology* **196** 497–507. (<https://doi.org/10.1677/JOE-07-0542>)
- Nilson JH, Bokar JA, Andersen B, Bohinski R, Kennedy G, Keri RA, Farmerie TA & Fenstermaker RA 1989 CRE-binding proteins interact cooperatively to enhance placental-specific expression of the glycoprotein hormone alpha-subunit gene. *Annals of the New York Academy of Sciences* **564** 77–85. (<https://doi.org/10.1111/j.1749-6632.1989.tb25889.x>)
- Ortolano GA, Haisenleder DJ, Dalkin AC, Iliff-Sizemore SA, Landefeld TD, Maurer RA & Marshall JC 1988 Follicle-stimulating hormone beta subunit messenger ribonucleic acid concentrations during the rat estrous cycle. *Endocrinology* **123** 2149–2151. (<https://doi.org/10.1210/endo-123-4-2149>)
- Otsuka F & Shimasaki S 2002 A novel function of bone morphogenetic protein-15 in the pituitary: selective synthesis and secretion of FSH by gonadotrophs. *Endocrinology* **143** 4938–4941. (<https://doi.org/10.1210/en.2002-220929>)
- Papavasiliou SS, Zmelli S, Khoury S, Landefeld TD, Chin WW & Marshall JC 1986 Gonadotropin-releasing hormone differentially regulates expression of the genes for luteinizing hormone alpha and beta subunits in male rats. *PNAS* **83** 4026–4029. (<https://doi.org/10.1073/pnas.83.11.4026>)
- Park KS, Kim KK & Kim KE 2015 Mx1 homeodomain transcription factor and TATA-binding protein interact to repress the expression of the glycoprotein hormone alpha subunit gene. *Biochemical and Biophysical Research Communications* **468** 326–330. (<https://doi.org/10.1016/j.bbrc.2015.10.102>)
- Paul SJ, Ortolano GA, Haisenleder DJ, Stewart JM, Shupnik MA & Marshall JC 1990 Gonadotropin subunit messenger RNA concentrations after blockade of gonadotropin-releasing hormone action: testosterone selectively increases follicle-stimulating hormone beta-subunit messenger RNA by posttranscriptional mechanisms. *Molecular Endocrinology* **4** 1943–1955. (<https://doi.org/10.1210/mend-4-12-1943>)
- Peltoketo H, Strauss L, Karjalainen R, Zhang M, Stamp GW, Segaloff DL, Poutanen M & Huhtaniemi IT 2010 Female mice expressing constitutively active mutants of FSH receptor present with a phenotype of premature follicle depletion and estrogen excess. *Endocrinology* **151** 1872–1883. (<https://doi.org/10.1210/en.2009-0966>)
- Perera-Marin G, Gutierrez CG, Murcia C, Leon H & Gonzalez-Padilla E 2008 Progesterone and the distribution of pituitary gonadotropin isoforms in cattle. *Animal Reproduction Science* **104** 164–176. (<https://doi.org/10.1016/j.anireprosci.2007.02.015>)
- Pierce JG & Parsons TF 1981 Glycoprotein hormones: structure and function. *Annual Review of Biochemistry* **50** 465–495. (<https://doi.org/10.1146/annurev.bi.50.070181.002341>)
- Piketty V, Kara E, Guillou F, Reiter E & Crepieux P 2006 Follicle-stimulating hormone (FSH) activates extracellular signal-regulated kinase phosphorylation independently of beta-arrestin- and dynamin-mediated FSH receptor internalization. *Reproductive Biology and Endocrinology* **4** 33. (<https://doi.org/10.1186/1477-7827-4-33>)
- Ponikwicka-Tyszko D, Chrusciel M, Stelmazewska J, Bernaczyk P, Sztachelska M, Sidorkiewicz I, Doroszko M, Tomaszewski J, Tapanainen JS, Huhtaniemi I, et al. 2016 Functional expression of FSH receptor in endometriotic lesions. *Journal of Clinical Endocrinology and Metabolism* **101** 2905–2914. (<https://doi.org/10.1210/jc.2016-1014>)
- Quintana J, Hipkin RW, Sanchez-Yague J & Ascoli M 1994 Follitropin (FSH) and a phorbol ester stimulate the phosphorylation of the FSH receptor in intact cells. *Journal of Biological Chemistry* **269** 8772–8779.
- Radu A, Pichon C, Camparo P, Antoine M, Allory Y, Couvelard A, Fromont G, Hai MT & Ghinea N 2010 Expression of follicle-stimulating hormone receptor in tumor blood vessels. *New England Journal of Medicine* **363** 1621–1630. (<https://doi.org/10.1056/NEJMoa1001283>)
- Reddy GR, Xie C, Lindaman LL & Coss D 2013 GnRH increases c-Fos half-life contributing to higher FSHbeta induction. *Molecular Endocrinology* **27** 253–265. (<https://doi.org/10.1210/me.2012-1168>)
- Reiter E & Lefkowitz RJ 2006 GRKs and beta-arrestins: roles in receptor silencing, trafficking and signaling. *Trends in Endocrinology and Metabolism* **17** 159–165. (<https://doi.org/10.1016/j.tem.2006.03.008>)
- Reiter E, Marion S, Robert F, Troispoux C, Boulay F, Guillou F & Crepieux P 2001 Kinase-inactive G-protein-coupled receptor kinases are able to attenuate follicle-stimulating hormone-induced signaling. *Biochemical and Biophysical Research Communications* **282** 71–78. (<https://doi.org/10.1006/bbrc.2001.4534>)
- Ringstrom SJ, McAndrews JM, Rahal JO & Schwartz NB 1991 Cortisol in vivo increases FSH beta mRNA selectively in pituitaries of male rats. *Endocrinology* **129** 2793–2795. (<https://doi.org/10.1210/endo-129-5-2793>)
- Ringstrom SJ, Szabo M, Kilen SM, Saberi S, Knox KL & Schwartz NB 1997 The antiprogesterins RU486 and ZK98299 affect follicle-stimulating hormone secretion differentially on estrus, but not on proestrus. *Endocrinology* **138** 2286–2290. (<https://doi.org/10.1210/endo.138.6.5161>)
- Roberson MS, Misra-Press A, Laurance ME, Stork PJ & Maurer RA 1995 A role for mitogen-activated protein kinase in mediating activation of the glycoprotein hormone alpha-subunit promoter by gonadotropin-releasing hormone. *Molecular and Cellular Biology* **15** 3531–3539. (<https://doi.org/10.1128/MCB.15.7.3531>)

- Roberson MS, Bliss SP, Xie J, Navratil AM, Farmerie TA, Wolfe MW & Clay CM 2005 Gonadotropin-releasing hormone induction of extracellular-signal regulated kinase is blocked by inhibition of calmodulin. *Molecular Endocrinology* **19** 2412–2423. (<https://doi.org/10.1210/me.2005-0094>)
- Robertson DM, Burger HG & Fuller PJ 2004 Inhibin/activin and ovarian cancer. *Endocrine-Related Cancer* **11** 35–49. (<https://doi.org/10.1677/erc.0.0110035>)
- Robinson LJ, Tourkova I, Wang Y, Sharrow AC, Landau MS, Yaroslavskiy BB, Sun L, Zaidi M & Blair HC 2010 FSH-receptor isoforms and FSH-dependent gene transcription in human monocytes and osteoclasts. *Biochemical and Biophysical Research Communications* **394** 12–17. (<https://doi.org/10.1016/j.bbrc.2010.02.112>)
- Roper LK, Briguglio JS, Evans CS, Jackson MB & Chapman ER 2015 Sex-specific regulation of follicle-stimulating hormone secretion by synaptotagmin 9. *Nature Communication* **6** 8645. (<https://doi.org/10.1038/ncomms9645>)
- Ruiz-Canada C, Kelleher DJ & Gilmore R 2009 Cotranslational and posttranslational N-glycosylation of polypeptides by distinct mammalian OST isoforms. *Cell* **136** 272–283. (<https://doi.org/10.1016/j.cell.2008.11.047>)
- Safwat N, Ninomiya-Tsuji J, Gore AJ & Miller WL 2005 Transforming growth factor beta-activated kinase 1 is a key mediator of ovine follicle-stimulating hormone beta-subunit expression. *Endocrinology* **146** 4814–4824. (<https://doi.org/10.1210/en.2005-0457>)
- Sairam MR & Krishnamurthy H 2001 The role of follicle-stimulating hormone in spermatogenesis: lessons from knockout animal models. *Archives of Medical Research* **32** 601–608. ([https://doi.org/10.1016/S0188-4409\(01\)00328-9](https://doi.org/10.1016/S0188-4409(01)00328-9))
- Sandoval-Guzman T, Gongrich C, Moliner A, Guo T, Wu H, Broberger C & Ibanez CF 2012 Neuroendocrine control of female reproductive function by the activin receptor ALK7. *FASEB Journal* **26** 4966–4976. (<https://doi.org/10.1096/fj.11-199059>)
- Sawangjaroen K, Anderson ST & Curlew JD 1997 Effects of pituitary adenylate cyclase-activating polypeptide (PACAP) and vasoactive intestinal polypeptide (VIP) on hormone secretion from sheep pituitary cells in vitro. *Journal of Neuroendocrinology* **9** 279–286. (<https://doi.org/10.1046/j.1365-2826.1997.00580.x>)
- Schmidt D, Ovitt CE, Anlag K, Fehsenfeld S, Gredsted L, Treier AC & Treier M 2004 The murine winged-helix transcription factor Foxl2 is required for granulosa cell differentiation and ovary maintenance. *Development* **131** 933–942. (<https://doi.org/10.1242/dev.00969>)
- Schmidt-Supprian M & Rajewsky K 2007 Vagaries of conditional gene targeting. *Nature Immunology* **8** 665–668. (<https://doi.org/10.1038/ni0707-665>)
- Schneyer A, Schoen A, Quigg A & Sidis Y 2003 Differential binding and neutralization of activins A and B by follistatin and follistatin like-3 (FSTL-3/FSRP/FLRG). *Endocrinology* **144** 1671–1674. (<https://doi.org/10.1210/en.2002-0203>)
- Schoderbek WE, Roberson MS & Maurer RA 1993 Two different DNA elements mediate gonadotropin releasing hormone effects on expression of the glycoprotein hormone alpha-subunit gene. *Journal of Biological Chemistry* **268** 3903–3910.
- Shi Y, Wang YF, Jayaraman L, Yang H, Massague J & Pavletich NP 1998 Crystal structure of a Smad MH1 domain bound to DNA: insights on DNA binding in TGF-beta signaling. *Cell* **94** 585–594. ([https://doi.org/10.1016/S0092-8674\(00\)81600-1](https://doi.org/10.1016/S0092-8674(00)81600-1))
- Shimada M, Hernandez-Gonzalez I, Gonzalez-Robayna I & Richards JS 2006 Paracrine and autocrine regulation of epidermal growth factor-like factors in cumulus oocyte complexes and granulosa cells: key roles for prostaglandin synthase 2 and progesterone receptor. *Molecular Endocrinology* **20** 1352–1365. (<https://doi.org/10.1210/me.2005-0504>)
- Shimasaki S, Koga M, Esch F, Cooksey K, Mercado M, Koba A, Ueno N, Ying SY, Ling N & Guillemin R 1988 Primary structure of the human follistatin precursor and its genomic organization. *PNAS* **85** 4218–4222. (<https://doi.org/10.1073/pnas.85.12.4218>)
- Shupnik MA 1990 Effects of gonadotropin-releasing hormone on rat gonadotropin gene transcription in vitro: requirement for pulsatile administration for luteinizing hormone-beta gene stimulation. *Molecular Endocrinology* **4** 1444–1450. (<https://doi.org/10.1210/mend-4-10-1444>)
- Shupnik MA & Fallest PC 1994 Pulsatile GnRH regulation of gonadotropin subunit gene transcription. *Neuroscience and Biobehavioral Reviews* **18** 597–599. ([https://doi.org/10.1016/0149-7634\(94\)90017-5](https://doi.org/10.1016/0149-7634(94)90017-5))
- Shupnik MA, Gharib SD & Chin WW 1988 Estrogen suppresses rat gonadotropin gene transcription in vivo. *Endocrinology* **122** 1842–1846. (<https://doi.org/10.1210/endo-122-5-1842>)
- Shupnik MA, Gharib SD & Chin WW 1989 Divergent effects of estradiol on gonadotropin gene transcription in pituitary fragments. *Molecular Endocrinology* **3** 474–480. (<https://doi.org/10.1210/mend-3-3-474>)
- Sidis Y, Tortoriello DV, Holmes WE, Pan Y, Keutmann HT & Schneyer AL 2002 Follistatin-related protein and follistatin differentially neutralize endogenous vs exogenous activin. *Endocrinology* **143** 1613–1624. (<https://doi.org/10.1210/endo.143.5.8805>)
- Silver BJ, Bokar JA, Virgin JB, Vallen EA, Milsted A & Nilson JH 1987 Cyclic AMP regulation of the human glycoprotein hormone alpha-subunit gene is mediated by an 18-base-pair element. *PNAS* **84** 2198–2202. (<https://doi.org/10.1073/pnas.84.8.2198>)
- Simoni M, Gromoll J & Nieschlag E 1997 The follicle-stimulating hormone receptor: biochemistry, molecular biology, physiology, and pathophysiology. *Endocrine Reviews* **18** 739–773. (<https://doi.org/10.1210/edrv.18.6.0320>)
- Simoni M, Weinbauer GF, Gromoll J & Nieschlag E 1999 Role of FSH in male gonadal function. *Annales D'Endocrinologie* **60** 102–106.
- Siraj A, Desestret V, Antoine M, Fromont G, Huerre M, Sanson M, Camparo P, Pichon C, Planeix F, Gonin J, et al. 2013 Expression of follicle-stimulating hormone receptor by the vascular endothelium in tumor metastases. *BMC Cancer* **13** 246. (<https://doi.org/10.1186/1471-2407-13-246>)
- Smitz J, Wolfenson C, Chappel S & Ruman J 2016 Follicle-stimulating hormone: a review of form and function in the treatment of infertility. *Reproductive Sciences* **23** 706–716. (<https://doi.org/10.1177/1933719115607992>)
- Sood P, Krek A, Zavolan M, Macino G & Rajewsky N 2006 Cell-type-specific signatures of microRNAs on target mRNA expression. *PNAS* **103** 2746–2751. (<https://doi.org/10.1073/pnas.0511045103>)
- Spady TJ, Shayya R, Thackray VG, Ehrensberger L, Bailey JS & Mellon PL 2004 Androgen regulates follicle-stimulating hormone beta gene expression in an activin-dependent manner in immortalized gonadotropes. *Molecular Endocrinology* **18** 925–940. (<https://doi.org/10.1210/me.2003-0115>)
- Stanislaus D, Janovick JA, Brothens S & Conn PM 1997 Regulation of G(q/11)alpha by the gonadotropin-releasing hormone receptor. *Molecular Endocrinology* **11** 738–746.
- Stanton PG, Burgon PG, Hearn MT & Robertson DM 1996 Structural and functional characterisation of hFSH and hLH isoforms. *Molecular and Cellular Endocrinology* **125** 133–141. ([https://doi.org/10.1016/S0303-7207\(96\)03958-5](https://doi.org/10.1016/S0303-7207(96)03958-5))
- Stelmazewska J, Chrusciel M, Doroszko M, Akerfelt M, Ponikwicka-Tyszkowski D, Nees M, Frentsch M, Li X, Kero J, Huhtaniemi I, et al. 2016 Revisiting the expression and function of follicle-stimulation hormone receptor in human umbilical vein endothelial cells. *Scientific Reports* **6** 37095. (<https://doi.org/10.1038/srep37095>)
- Stilley JA, Christensen DE, Dahlem KB, Guan R, Santillan DA, England SK, Al-Hendy A, Kirby PA & Segaloff DL 2014a FSH receptor (FSHR) expression in human extragonadal reproductive tissues and the developing placenta, and the impact of its deletion on pregnancy in mice. *Biology of Reproduction* **91** 74. (<https://doi.org/10.1095/biolreprod.114.118562>)

- Stilley JA, Guan R, Duffy DM & Segaloff DL 2014b Signaling through FSH receptors on human umbilical vein endothelial cells promotes angiogenesis. *Journal of Clinical Endocrinology and Metabolism* **99** E813–E820. (<https://doi.org/10.1210/jc.2013-3186>)
- Stocco C, Baumgarten SC, Armouti M, Fierro MA, Winston NJ, Scoccia B & Zamah AM 2017 Genome-wide interactions between FSH and insulin-like growth factors in the regulation of human granulosa cell differentiation. *Human Reproduction* **32** 905–914. (<https://doi.org/10.1093/humrep/dex002>)
- Stockell Hartree A & Renwick AG 1992 Molecular structures of glycoprotein hormones and functions of their carbohydrate components. *Biochemical Journal* **287** 665–679. (<https://doi.org/10.1042/bj2870665>)
- Stojilkovic SS, Reinhart J & Catt KJ 1994 Gonadotropin-releasing hormone receptors: structure and signal transduction pathways. *Endocrine Reviews* **15** 462–499. (<https://doi.org/10.1210/edrv-15-4-462>)
- Strahl BD, Huang HJ, Pedersen NR, Wu JC, Ghosh BR & Miller WL 1997 Two proximal activating protein-1-binding sites are sufficient to stimulate transcription of the ovine follicle-stimulating hormone-beta gene. *Endocrinology* **138** 2621–2631. (<https://doi.org/10.1210/endo.138.6.5205>)
- Strahl BD, Huang HJ, Sebastian J, Ghosh BR & Miller WL 1998 Transcriptional activation of the ovine follicle-stimulating hormone beta-subunit gene by gonadotropin-releasing hormone: involvement of two activating protein-1-binding sites and protein kinase C. *Endocrinology* **139** 4455–4465. (<https://doi.org/10.1210/endo.139.11.6281>)
- Su XY, Zou X, Chen QZ, Zeng YH, Shao Y, He BC & Liu H 2017 Follicle-stimulating hormone beta-subunit potentiates bone morphogenetic protein 9-induced osteogenic differentiation in mouse embryonic fibroblasts. *Journal of Cellular Biochemistry* **118** 1792–1802. (<https://doi.org/10.1002/jcb.25849>)
- Sun L, Peng Y, Sharrow AC, Iqbal J, Zhang Z, Papachristou DJ, Zaidi S, Zhu LL, Yaroslavskiy BB, Zhou H, *et al.* 2006 FSH directly regulates bone mass. *Cell* **125** 247–260. (<https://doi.org/10.1016/j.cell.2006.01.051>)
- Sundaresan S, Colin IM, Pestell RG & Jameson JL 1996 Stimulation of mitogen-activated protein kinase by gonadotropin-releasing hormone: evidence for the involvement of protein kinase C. *Endocrinology* **137** 304–311. (<https://doi.org/10.1210/endo.137.1.8536629>)
- Suszko MI, Lo DJ, Suh H, Camper SA & Woodruff TK 2003 Regulation of the rat follicle-stimulating hormone beta-subunit promoter by activin. *Molecular Endocrinology* **17** 318–332. (<https://doi.org/10.1210/me.2002-0081>)
- Suszko MI, Balkin DM, Chen Y & Woodruff TK 2005 Smad3 mediates activin-induced transcription of follicle-stimulating hormone beta-subunit gene. *Molecular Endocrinology* **19** 1849–1858. (<https://doi.org/10.1210/me.2004-0475>)
- Szabo M, Kilen SM, Saberi S, Ringstrom SJ & Schwartz NB 1998 Antiprogesterins suppress basal and activin-stimulated follicle-stimulating hormone secretion in an estrogen-dependent manner. *Endocrinology* **139** 2223–2228. (<https://doi.org/10.1210/endo.139.5.6015>)
- Thackray VG, McGillivray SM & Mellon PL 2006 Androgens, progestins, and glucocorticoids induce follicle-stimulating hormone beta-subunit gene expression at the level of the gonadotrope. *Molecular Endocrinology* **20** 2062–2079. (<https://doi.org/10.1210/me.2005-0316>)
- Thomas CM, Span PN, Smeenk JM, Hanssen RG, Braat DD & Sweep FC 2009 Occurrence of postmenopausal-like acidic follicle-stimulating hormone (FSH) isoforms precedes the rise of FSH before menopause. *Fertility and Sterility* **92** 613–619. (<https://doi.org/10.1016/j.fertnstert.2008.06.012>)
- Thomas RM, Nechamen CA, Mazurkiewicz JE, Ulloa-Aguirre A & Dias JA 2011 The adapter protein APPL1 links FSH receptor to inositol 1,4,5-trisphosphate production and is implicated in intracellular Ca(2+) mobilization. *Endocrinology* **152** 1691–1701. (<https://doi.org/10.1210/en.2010-1353>)
- Thompson IR, Ciccone NA, Zhou Q, Xu S, Khogeer A, Carroll RS & Kaiser UB 2016 GnRH pulse frequency control of Fshb Gene expression is mediated via ERK1/2 regulation of ICER. *Molecular Endocrinology* **30** 348–360. (<https://doi.org/10.1210/me.2015-1222>)
- Timossi CM, Barrios-de-Tomasi J, Gonzalez-Suarez R, Arranz MC, Padmanabhan V, Conn PM & Ulloa-Aguirre A 2000 Differential effects of the charge variants of human follicle-stimulating hormone. *Journal of Endocrinology* **165** 193–205. (<https://doi.org/10.1677/joe.0.1650193>)
- Tran S, Zhou X, Lafleur C, Calderon MJ, Ellsworth BS, Kimmins S, Boehm U, Treier M, Boerboom D & Bernard DJ 2013 Impaired fertility and FSH synthesis in gonadotrope-specific Foxl2 knockout mice. *Molecular Endocrinology* **27** 407–421. (<https://doi.org/10.1210/me.2012-1286>)
- Troispoux C, Guillou F, Elalouf JM, Firsov D, Iacovelli L, De Blasi A, Combarnous Y & Reiter E 1999 Involvement of G protein-coupled receptor kinases and arrestins in desensitization to follicle-stimulating hormone action. *Molecular Endocrinology* **13** 1599–1614. (<https://doi.org/10.1210/mend.13.9.0342>)
- Tsang J, Zhu J & van Oudenaarden A 2007 MicroRNA-mediated feedback and feedforward loops are recurrent network motifs in mammals. *Molecular Cell* **26** 753–767. (<https://doi.org/10.1016/j.molcel.2007.05.018>)
- Tsutsumi M, Zhou W, Millar RP, Mellon PL, Roberts JL, Flanagan CA, Dong K, Gillo B & Sealfon SC 1992 Cloning and functional expression of a mouse gonadotropin-releasing hormone receptor. *Molecular Endocrinology* **6** 1163–1169.
- Uda M, Ottolenghi C, Crisponi L, Garcia JE, Deiana M, Kimber W, Forabosco A, Cao A, Schlessinger D & Pilia G 2004 Foxl2 disruption causes mouse ovarian failure by pervasive blockage of follicle development. *Human Molecular Genetics* **13** 1171–1181. (<https://doi.org/10.1093/hmg/ddh124>)
- Ulloa-Aguirre A, Dias JA & Bousfield GR 2017 Gonadotropins. In *Endocrinology of the Testis and Male Reproduction*, pp 1–52. Eds M Simoni & I Huhtaniemi. Springer International: Cham, Switzerland.
- Vale W, Rivier J, Vaughan J, McClintock R, Corrigan A, Woo W, Karr D & Spiess J 1986 Purification and characterization of an FSH releasing protein from porcine ovarian follicular fluid. *Nature* **321** 776–779. (<https://doi.org/10.1038/321776a0>)
- Velthut-Meikas A, Simm J, Tuuri T, Tapanainen JS, Metsis M & Salumets A 2013 Research resource: small RNA-seq of human granulosa cells reveals miRNAs in FSHR and aromatase genes. *Molecular Endocrinology* **27** 1128–1141. (<https://doi.org/10.1210/me.2013-1058>)
- Walton WJ, Nguyen VT, Butnev VY, Singh V, Moore WT & Bousfield GR 2001 Characterization of human FSH isoforms reveals a nonglycosylated beta-subunit in addition to the conventional glycosylated beta-subunit. *Journal of Clinical Endocrinology and Metabolism* **86** 3675–3685. (<https://doi.org/10.1210/jcem.86.8.7712>)
- Wang Y & Bernard DJ 2012 Activin A induction of murine and ovine follicle-stimulating hormone beta transcription is SMAD-dependent and TAK1 (MAP3K7)/p38 MAPK-independent in gonadotrope-like cells. *Cell Signaling* **24** 1632–1640. (<https://doi.org/10.1016/j.cellsig.2012.04.006>)
- Wang Y, Tan J, Sutton-Smith M, Ditto D, Panico M, Campbell RM, Varki NM, Long JM, Jaeken J, Levinson SR, *et al.* 2001 Modeling human congenital disorder of glycosylation type IIa in the mouse: conservation of asparagine-linked glycan-dependent functions in mammalian physiology and insights into disease pathogenesis. *Glycobiology* **11** 1051–1070. (<https://doi.org/10.1093/glycob/11.12.1051>)

- Wang Y, Fortin J, Lamba P, Bonomi M, Persani L, Roberson MS & Bernard DJ 2008 Activator protein-1 and smad proteins synergistically regulate human follicle-stimulating hormone beta-promoter activity. *Endocrinology* **149** 5577–5591. (<https://doi.org/10.1210/en.2008-0220>)
- Wang H, Larson M, Jablonka-Shariff A, Pearl CA, Miller WL, Conn PM, Boime I & Kumar TR 2014a Redirecting intracellular trafficking and the secretion pattern of FSH dramatically enhances ovarian function in mice. *PNAS* **111** 5735–5740. (<https://doi.org/10.1073/pnas.1321404111>)
- Wang Q, Chikina MD, Pincas H & Sealson SC 2014b Homer1 alternative splicing is regulated by gonadotropin-releasing hormone and modulates gonadotropin gene expression. *Molecular and Cellular Biology* **34** 1747–1756. (<https://doi.org/10.1128/MCB.01401-13>)
- Wang Y, Ho CC, Bang E, Rejon CA, Libasci V, Pertchenko P, Hebert TE & Bernard DJ 2014c Bone morphogenetic protein 2 stimulates noncanonical SMAD2/3 signaling via the BMP type 1A receptor in gonadotrope-like cells: implications for FSH synthesis. *Endocrinology* **155** 1970–1981. (<https://doi.org/10.1210/en.2013-1741>)
- Wang H, Graham I, Hastings R, Gunewardena S, Brinkmeier ML, Conn PM, Camper SA & Kumar TR 2015 Gonadotrope-specific deletion of Dicer results in severely suppressed gonadotropins and fertility defects. *Journal of Biological Chemistry* **290** 2699–2714. (<https://doi.org/10.1074/jbc.M114.621565>)
- Wang H, Butnev V, Bousfield GR & Kumar TR 2016a A human FSHB transgene encoding the double N-glycosylation mutant (Asn(7Delta) Asn(24Delta)) FSHbeta subunit fails to rescue Fshb null mice. *Molecular and Cellular Endocrinology* **426** 113–124. (<https://doi.org/10.1016/j.mce.2016.02.015>)
- Wang H, May J, Butnev V, Shuai B, May JV, Bousfield GR & Kumar TR 2016b Evaluation of in vivo bioactivities of recombinant hypo- (FSH21/18) and fully- (FSH24) glycosylated human FSH isoforms in Fshb null mice. *Molecular and Cellular Endocrinology* **437** 224–236. (<https://doi.org/10.1016/j.mce.2016.08.031>)
- Wayne CM, Fan HY, Cheng X & Richards JS 2007 Follicle-stimulating hormone induces multiple signaling cascades: evidence that activation of Rous sarcoma oncogene, RAS, and the epidermal growth factor receptor are critical for granulosa cell differentiation. *Molecular Endocrinology* **21** 1940–1957. (<https://doi.org/10.1210/me.2007-0020>)
- Weiss J, Guendner MJ, Halvorson LM & Jameson JL 1995 Transcriptional activation of the follicle-stimulating hormone beta-subunit gene by activin. *Endocrinology* **136** 1885–1891. (<https://doi.org/10.1210/endo.136.5.7720634>)
- West CR, Carlson NE, Lee JS, McNeilly AS, Sharma TP, Ye W & Padmanabhan V 2002 Acidic mix of FSH isoforms are better facilitators of ovarian follicular maturation and E2 production than the less acidic. *Endocrinology* **143** 107–116. (<https://doi.org/10.1210/endo.143.1.8601>)
- Whalen EJ, Rajagopal S & Lefkowitz RJ 2011 Therapeutic potential of beta-arrestin- and G protein-biased agonists. *Trends in Molecular Medicine* **17** 126–139. (<https://doi.org/10.1016/j.molmed.2010.11.004>)
- Wide L & Eriksson K 2013 Dynamic changes in glycosylation and glycan composition of serum FSH and LH during natural ovarian stimulation. *Upsala Journal of Medical Sciences* **118** 153–164. (<https://doi.org/10.3109/03009734.2013.782081>)
- Wierman ME & Wang C 1990 Androgen selectively stimulates follicle-stimulating hormone-beta mRNA levels after gonadotropin-releasing hormone antagonist administration. *Biology of Reproduction* **42** 563–571. (<https://doi.org/10.1095/biolreprod42.3.563>)
- Williams SA & Stanley P 2009 Oocyte-specific deletion of complex and hybrid N-glycans leads to defects in preovulatory follicle and cumulus mass development. *Reproduction* **137** 321–331. (<https://doi.org/10.1530/REP-07-0469>)
- Wilson CA, Leigh AJ & Chapman AJ 1990 Gonadotrophin glycosylation and function. *Journal of Endocrinology* **125** 3–14. (<https://doi.org/10.1677/joe.0.1250003>)
- Wojcik-Gladysz A, Wankowska M, Gajewska A, Misztal T, Zielinska-Gorska M, Szlis M & Polkowska J 2016 Effects of intracerebroventricular infusions of ghrelin on secretion of follicle-stimulating hormone in peripubertal female sheep. *Reproduction, Fertility, and Development* **28** 2065–2074. (<https://doi.org/10.1071/RD16028>)
- Wreford NG, Rajendra Kumar T, Matzuk MM & de Kretser DM 2001 Analysis of the testicular phenotype of the follicle-stimulating hormone beta-subunit knockout and the activin type II receptor knockout mice by stereological analysis. *Endocrinology* **142** 2916–2920. (<https://doi.org/10.1210/endo.142.7.8230>)
- Wurmbach E, Yuen T, Ebersole BJ & Sealson SC 2001 Gonadotropin-releasing hormone receptor-coupled gene network organization. *Journal of Biological Chemistry* **276** 47195–47201. (<https://doi.org/10.1074/jbc.M108716200>)
- Xiao K, McClatchy DB, Shukla AK, Zhao Y, Chen M, Shenoy SK, Yates JR 3rd & Lefkowitz RJ 2007 Functional specialization of beta-arrestin interactions revealed by proteomic analysis. *PNAS* **104** 12011–12016. (<https://doi.org/10.1073/pnas.0704849104>)
- Xie H, Cherrington BD, Meadows JD, Witham EA & Mellon PL 2013 Mx1 homeodomain protein represses the alphaGSU and GnRH receptor genes during gonadotrope development. *Molecular Endocrinology* **27** 422–436. (<https://doi.org/10.1210/me.2012-1289>)
- Xie H, Hoffmann HM, Meadows JD, Mayo SL, Trang C, Leming SS, Maruggi C, Davis SW, Larder R & Mellon PL 2015 Homeodomain proteins SIX3 and SIX6 regulate gonadotrope-specific genes during pituitary development. *Molecular Endocrinology* **29** 842–855. (<https://doi.org/10.1210/me.2014-1279>)
- Yang P & Roy SK 2006 A novel mechanism of FSH regulation of DNA synthesis in the granulosa cells of hamster preantral follicles: involvement of a protein kinase C-mediated MAP kinase 3/1 self-activation loop. *Biology of Reproduction* **75** 149–157. (<https://doi.org/10.1095/biolreprod.105.050153>)
- Yao N, Lu CL, Zhao JJ, Xia HF, Sun DG, Shi XQ, Wang C, Li D, Cui Y & Ma X 2009 A network of miRNAs expressed in the ovary are regulated by FSH. *Frontiers in Bioscience* **14** 3239–3245. (<https://doi.org/10.2741/3447>)
- Yao N, Yang BQ, Liu Y, Tan XY, Lu CL, Yuan XH & Ma X 2010 Follicle-stimulating hormone regulation of microRNA expression on progesterone production in cultured rat granulosa cells. *Endocrine* **38** 158–166. (<https://doi.org/10.1007/s12020-010-9345-1>)
- Ye RS, Xi QY, Qi Q, Cheng X, Chen T, Li H, Kallon S, Shu G, Wang SB, Jiang QY, et al. 2013 Differentially expressed miRNAs after GnRH treatment and their potential roles in FSH regulation in porcine anterior pituitary cell. *PLoS ONE* **8** e57156. (<https://doi.org/10.1371/journal.pone.0057156>)
- Ye RS, Li M, Li CY, Qi QE, Chen T, Cheng X, Wang SB, Shu G, Wang LN, Zhu XT, et al. 2017 miR-361-3p regulates FSH by targeting FSHB in a porcine anterior pituitary cell model. *Reproduction* **153** 341–349. (<https://doi.org/10.1530/REP-16-0373>)
- Ying SY, Becker A, Swanson G, Tan P, Ling N, Esch E, Ueno N, Shimasaki S & Guillemin R 1987 Follistatin specifically inhibits pituitary follicle stimulating hormone release in vitro. *Biochemical and Biophysical Research Communications* **149** 133–139. ([https://doi.org/10.1016/0006-291X\(87\)91614-7](https://doi.org/10.1016/0006-291X(87)91614-7))
- Zafeiriou S, Loutradis D & Michalas S 2000 The role of gonadotropins in follicular development and their use in ovulation induction protocols for assisted reproduction. *European Journal of Contraception and Reproductive Health Care* **5** 157–167. (<https://doi.org/10.1080/13625180008500389>)
- Zambrano E, Zarinan T, Olivares A, Barrios-de-Tomasi J & Ulloa-Aguirre A 1999 Receptor binding activity and in vitro biological activity of the human FSH charge isoforms as disclosed by

- heterologous and homologous assay systems: implications for the structure-function relationship of the FSH variants. *Endocrine* **10** 113–121. (<https://doi.org/10.1385/ENDO:10:2:113>)
- Zelevnik AJ, Saxena D & Little-Ihrig L 2003 Protein kinase B is obligatory for follicle-stimulating hormone-induced granulosa cell differentiation. *Endocrinology* **144** 3985–3994. (<https://doi.org/10.1210/en.2003-0293>)
- Zhou P, Baumgarten SC, Wu Y, Bennett J, Winston N, Hirshfeld-Cytron J & Stocco C 2013 IGF-I signaling is essential for FSH stimulation of AKT and steroidogenic genes in granulosa cells. *Molecular Endocrinology* **27** 511–523. (<https://doi.org/10.1210/me.2012-1307>)
- Zhu C, Ji Y, Liu S & Bian Z 2016a Follicle-stimulating hormone enhances alveolar bone resorption via upregulation of cyclooxygenase-2. *American Journal of Translational Research* **8** 3861–3871.
- Zhu C, Xu Q, Pan D, Xu Y, Liu P, Yang R, Wang L, Sun X, Luo S & Yang M 2016b Prostate cancer imaging of FSHR antagonist modified with a hydrophilic linker. *Contrast Media and Molecular Imaging* **11** 99–105. (<https://doi.org/10.1002/cmmi.1662>)

Received in final form 29 January 2018

Accepted 7 February 2018

Accepted Preprint published online 7 February 2018